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Summary
Background Chronic hepatitis C virus (HCV) infection in patients with stage 4–5 chronic kidney disease increases the 
risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment 
options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and 
stage 4–5 chronic kidney disease.
Methods In this phase 3 randomised study of safety and observational study of efficacy, patients with HCV genotype 
1 infection and chronic kidney disease (stage 4–5 with or without haemodialysis dependence) were randomly assigned 
to receive grazoprevir (100 mg, NS3/4A protease inhibitor) and elbasvir (50 mg, NS5A inhibitor; immediate treatment 
group) or placebo (deferred treatment group) once daily for 12 weeks. Randomisation was done centrally with an 
interactive voice response system. An additional cohort of patients who were not randomised received the same 
regimen open-label and underwent intensive pharmacokinetic sampling. The primary efficacy outcome was a non-
randomised comparison of sustained virological response at 12 weeks (SVR12) after the end of therapy for the 
combined immediate treatment group and the pharmacokinetic population with a historical control. The primary 
safety outcome was a randomised comparison between the immediate treatment group and the deferred treatment 
group. After 4 weeks of follow-up (study week 16), unmasking occurred and patients in the deferred treatment group 
received grazoprevir and elbasvir. The primary efficacy hypothesis was tested at a two-sided significance level (type I 
error) of 0·05 using an exact test for a binomial proportion. Safety event rates were compared between immediate 
treatment and deferred treatment groups using the stratified Miettinen and Nurminen method with baseline dialysis 
status as the strata. The study is registered at ClinicalTrials.gov, number NCT02092350.
Findings 224 patients were randomly assigned to the immediate treatment group with grazoprevir and elbasvir 
(n=111) or the deferred treatment group (n=113), and 11 were assigned to the intensive pharmacokinetic population. 
Overall, 179 (76%) were haemodialysis-dependent, 122 (52%) had HCV genotype 1a infection, 189 (80%) were HCV 
treatment-naive, 14 (6%) were cirrhotic, and 108 (46%) were African American. Of the 122 patients receiving 
grazoprevir and elbasvir, six were excluded from the primary efficacy analysis for non-virological reasons (death, 
lost-to-follow-up [n=2], non-compliance, patient withdrawal, and withdrawal by physician for violent behaviour). No 
patients in the combined immediate treatment group and intensive pharmacokinetic population and five (4%) in 
the deferred treatment group discontinued because of an adverse event. Most common adverse events were 
headache, nausea, and fatigue, occurring at similar frequencies in patients receiving active and placebo drugs. 
SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99% (95% CI 
95·3–100·0; 115/116), with one relapse 12 weeks after end of treatment when compared with a historical control 
of 45%, based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV 
who are on haemodialysis.
Interpretation Once-daily grazoprevir and elbasvir for 12 weeks had a low rate of adverse events and was effective in 
patients infected with HCV genotype 1 and stage 4–5 chronic kidney disease.
Funding Merck Sharp & Dohme Corp.
Introduction
Hepatitis C infection accelerates the decline in kidney 
function in patients with chronic kidney disease and 
increases mortality among patients on haemodialysis1 
compared with patients not infected with hepatitis C on 
dialysis.2–6 Studies among kidney transplant patients show 
infection with hepatitis C also has an adverse effect on 
patient and graft survival.7–9 These data suggest that 
clearance of hepatitis C infection among patients with 
stage 4–5 chronic kidney disease (estimated glomerular 
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filtration rate [eGFR] ≤29 mL/min per 1·73 m² or on 
dialysis), especially those who are candidates for kidney 
transplantation, is of great importance.
Treatment options for patients with hepatitis C 
infection and stage 4–5 chronic kidney disease remain 
suboptimum. Approved all-oral therapies are not ideal 
regimens because they contain drugs whose metabolites 
are cleared by the kidney (such as sofosbuvir) or because 
they need co-administration with ribavirin, which is 
associated with anaemia.
Grazoprevir, a hepatitis C virus (HCV) NS3/4A protease 
inhibitor, and elbasvir, an NS5A protein inhibitor, are 
undergoing clinical assessment as a once-daily regimen for 
the treatment of HCV genotype 1, 4, and 6 infections.10–14 
Phase 1 studies have shown that less than 1% of grazoprevir 
and elbasvir are renally excreted, and that dose adjustments 
of grazoprevir or elbasvir are not needed in the setting of 
non-dialysis-dependent stage 4–5 chronic kidney disease 
and dialysis-dependent stage 5 chronic kidney disease.15 
C-SURFER (Hepatitis C: Study to Understand Renal 
Failure’s Effect on Responses) is the first phase 3 study of 
an all-oral HCV regimen in patients with stage 4–5 chronic 
kidney disease and HCV genotype 1 infection. The aims of 
the study were to assess the efficacy, safety, and tolerability 
of grazoprevir plus elbasvir in patients with HCV genotype 
1 infection and with chronic kidney disease stage 4–5.
Methods
Study design and participants
C-SURFER is a multicentre, phase 3, double-blind study 
comprising a randomised study of safety and an 
observational study of efficacy. Adult patients infected with 
HCV genotype 1 and with chronic kidney disease (stage 4–5 
with or without haemodialysis dependence) were selected 
for inclusion. Complete eligibility criteria are provided in 
the study protocol. Chronic kidney disease stages 4 and 5 
were defined based on eGFR (according to the Modification 
of Diet in Renal Disease [MDRD]-4 equation)16 15–29 mL/
min per 1·73 m² and less than 15 mL/min per 1·73 m² or 
on dialysis, respectively. Patients were either treatment-
naive for HCV or had previously received an interferon 
regimen. Liver staging was based on biopsy within 
24 months of enrolment; Fibroscan within 12 months of 
enrolment; or a combination of Fibrotest score greater than 
0·75 and an AST to platelet ratio of greater than 2.17–19
The study was done at 68 centres in the USA, Argentina, 
Australia, Canada, Estonia, France, Israel, South Korea, 
Lithuania, Netherlands, Spain, and Sweden in accordance 
with the Declaration of Helsinki, the International 
Conference on Harmonization guidelines, and other 
regulations governing clinical study conduct. The protocol 
was approved by an independent ethics committee or 
institutional review board at each participating site. All 
patients provided written informed consent.
Randomisation and masking
Participants were randomly assigned (1:1) to receive 
grazoprevir 100 mg and elbasvir 50 mg once daily 
(immediate treatment group) or placebo (deferred 
treatment group) for 12 weeks. 4 weeks after the end of 
treatment (week 16), patients and site personnel were 
unmasked, and those randomised to the deferred 
Research in context
Evidence before this study
Patients with stage 4–5 chronic kidney disease and hepatitis C 
infection have few treatment options for hepatitis C virus (HCV). 
At the time this study was designed, the Kidney Disease: 
Improving Global Outcomes (KDIGO) recommended treatment 
was interferon or pegylated interferon. Some investigators also 
explored adding ribavirin to pegylated interferon. Unfortunately, 
these regimens are associated with treatment-limiting toxic 
effects and suboptimum efficacy. We searched PubMed for 
clinical trials published before Jan 31, 2015, describing the 
treatment of hepatitis C in patients with advanced chronic 
kidney disease. Although this search returned a total of 
97 relevant articles, the data on this subject are summarised 
most concisely in a series of meta-analyses. The most recent of 
these meta-analyses (based on data from 28 clinical trials done 
between 1990 and 2006, and including 645 patients) suggests 
that interferon or pegylated interferon monotherapy was 
associated with a sustained virological response (SVR) in about 
one in three patients when treated for 16–48 weeks, whereas 
about 20–25% of patients did not complete treatment. In the 
past 5 years, the introduction of direct-acting antiviral therapies 
has dramatically improved treatment options for patients with 
hepatitis C. High rates of SVR, coupled with improved tolerability, 
are now available to many patients with HCV infection; however, 
in our literature review, we were unable to identify any published 
studies of direct-acting antiviral therapies in patients with 
advanced chronic kidney disease. Thus, patients with hepatitis C 
and stage 4–5 chronic kidney disease remain underserved by 
current direct-acting antiviral hepatitis C treatment regimens.
Added value of this study
This study is the first phase 3 study to assess an interferon-free, 
ribavirin-free, all-oral treatment regimen for patients with HCV 
infection and advanced (stage 4–5) chronic kidney disease. 
Patients receiving grazoprevir plus elbasvir for 12 weeks had a low 
rate of adverse events compared with a deferred treament group 
and achieved a 99% SVR12 compared with a historical control.
Implications of all the available evidence
Grazoprevir and elbasvir is an investigational medicine and is 
not approved for the treatment of HCV infection. However, 
data from the present study suggest that the availability of a 
grazoprevir and elbasvir regimen for patients with stage 4–5 
chronic kidney disease could represent a marked improvement 
in treatment for this significantly underserved patient group.
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treatment group received grazoprevir 100 mg and elbasvir 
50 mg once daily for 12 weeks (appendix). An additional 
cohort received open-label grazoprevir 100 mg and 
elbasvir 50 mg once daily for 12 weeks and underwent 
intensive pharmacokinetic sampling. Patients were 
recruited on a voluntary basis at study sites with expertise 
in conducting pharmacokinetic studies.
Randomisation for the safety study was done centrally 
using an interactive voice response system and stratified 
according to dialysis (yes/no) and presence of diabetes 
(yes/no) with a block size of 4. Grazoprevir, elbasvir, and 
placebos were manufactured to preserve masking 
(confirmed as visually identical) and packaged identically. 
All clinical supplies were provided by Merck & Co., Inc. 
Patients, investigators, and site personnel were masked to 
treatment assignment.
Procedures
Blood samples for assessment of HCV RNA were 
collected at baseline, at treatment weeks 1, 2, 3, 4, 6, 8, 10, 
and 12, and at 4, 12, and 24 weeks after end of treatment. 
Plasma HCV RNA concentrations were measured using 
Roche COBAS Ampliprep/COBAS Taqman HCV test 
v2.0 (Roche, Indianapolis, IN, USA) with a lower limit of 
quantification of less than 15 IU/mL. Blood samples for 
assessment of viral resistance were collected at baseline 
from all patients, and at virological failure for patients 
with HCV RNA greater than 1000 IU/mL who met criteria 
for virological failure. For patients on haemodialysis, 
laboratory sampling was done before dialysis.
Patients underwent routine laboratory testing, 
electrocardiograms, and symptom-directed physical 
examinations at baseline, and during, and after completion 
of treatment. Adverse events were graded according to a 
standardised scale (study protocol, appendix).
The deferred treatment group served as an internal 
control for potential safety signals in the immediate 
treatment group. Active therapy in the deferred 
treatment group is ongoing: data described herein are 
observations from the initial placebo treatment period 
plus 14 days (results of the deferred open-label treatment 
with grazoprevir and elbasvir will be presented 
elsewhere). All patients will be followed for 24 weeks 
after completion of therapy.
See Online for appendix
Figure 1: Trial profile
For the deferred treatment group, this figure does not show two deaths (pneumonia and unknown cause of death) that occurred after completion of treatment. 
In total, there were three deaths in the deferred treatment group (aortic aneurysm, pneumonia, and unknown cause of death): one patient discontinued due to an 
adverse event and then died (listed as discontinued). One patient in the immediate-treatment group discontinued study drug due to a kidney transplant at treatment 
week 4 but was not excluded from the modified full analysis set population because the patient continued to participate in the study, remaining in follow-up despite 
early discontinuation of the study drug.
328 screened patients
91 did not pass screening
 2 trial enrolment closed
 1 lost to follow-up
 88 screen failure
111 had immediate treatment
Grazoprevir 100 mg and 
elbasvir 50 mg for 
12 weeks
113 had deferred treatment 
Matched placebo for 
12 weeks then grazoprevir 
100 mg and elbasvir 
50 mg fixed-dose
 combination tablet for 
 12 weeks








 1 kidney transplant
 1 lost to follow-up
 1 non-compliance
 1 withdrawal by patient
6 discontinued treatment
 5 adverse events
 1 lost to follow-up
1 did not receive one or
 more doses of study
 drug because of
 pre-study adverse event
11 in the intensive
 pharmacokinetic population:
 grazoprevir 100 mg and elbasvir
50 mg for 12 weeks
11 completed treatment
1 did not receive one or
 more doses of study
 drug due to failure at
 screening
1 discontinued follow-up
 due to violent behaviour
226 randomly assigned
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An external data monitoring committee met when 
50% of patients had completed treatment week 4 or 
discontinued before treatment week 4 and again when 
all patients had completed treatment week 8 or 
discontinued before treatment week 8. After each 
meeting, it was recommended the study continue as 
planned.
Outcomes
The primary efficacy outcome was a non-randomised 
comparison of sustained virological response at 12 weeks 
after the end of therapy (SVR12) for patients in the 
immediate treatment group and intensive pharma-
cokinetic population versus historical control patients 
with a reference SVR12 of 45% (appendix). Relapse was 
defined as detectable HCV RNA following the end of 
therapy, after undetectable at end of treatment. The 
primary safety outcome was a comparison between the 
randomised immediate treatment and deferred treatment 
groups. Tier 1 safety events were defined as alanine 
aminotransferase (ALT) or aspartate aminotransferase 
(AST) greater than 500 IU/L; ALT or AST greater than 
three times the baseline and greater than 100 IU/L; 
alkaline phosphatase greater than three times the upper 
limit of normal. Tier 2 safety events were defined as 
patients with one or more adverse events, a drug-related 
adverse event, a serious adverse event, a serious renal 
adverse event, a serious and drug-related adverse event, 
an adverse event leading to discontinuation from 
treatment, and changes in renal function (increasing 
dialysis frequency in patients on haemodialysis at 
baseline, initiation of maintenance haemodialysis in 
patients not on haemodialysis at baseline, or an increase 
in chronic kidney disease stage). Tier 2 safety parameters 
also included change from baseline in serum creatinine, 
blood urea nitrogen, and eGFR in patients not receiving 
haemodialysis at baseline. Pharmacokinetic data are not 
reported here. Secondary endpoints not reported here are 
the SVR24 for the immediate treatment group and SVR12 
for the active treatment phase of the deferred group.
Statistical analysis
According to the primary hypothesis, patients receiving 
grazoprevir and elbasvir in the immediate treatment 
group and intensive pharmacokinetic population will 
achieve an SVR12 rate higher than the reference rate of 
45% (appendix). This value is based on a meta-analysis 
indicating an SVR rate of 39% in patients with stages 3–5 
chronic kidney disease receiving interferon monotherapy20 
and an SVR of 40% in patients with HCV genotype 1 
infection without renal disease receiving peginterferon 
and ribavirin.21 The primary hypothesis was tested at a 
two-sided significance level (type I error) of 0·05 using an 
exact test for a binomial proportion. A 95% CI was also 
constructed for the SVR12 rate using the Clopper-Pearson 
method on non-randomised populations.
The modified full analysis set served as the primary 
population for the analysis of efficacy, and included 
patients assigned to the immediate treatment group or 
assigned to the intensive pharmacokinetic group, 















Male 11 (100%) 81 (73·0%) 80 (70·8%) 172 (73·2%)
Female 0 30 (27·0%) 33 (29·2%) 63 (26·8%)
Age, years 58·2 (6·8) 56·5 (9·1) 55·2 (10·1) 56·0 (9·5)
Race
White 6 (54·5%) 55 (49·5%) 48 (42·5%) 109 (46·4%)
African-American 5 (45·5%) 50 (45·0%) 53 (46·9%) 108 (46·0%)
Asian 0 5 (4·5%) 9 (8·0%) 14 (6·0%)
Other 0 1 (0·9%) 3 (2·7%) 4 (1·7%)
Ethnic origin
Hispanic–Latino 2 (18·2%) 11 (9·9%) 14 (12·4%) 27 (11·5%)
Not Hispanic–Latino 9 (81·8%) 98 (88·3%) 99 (87·6%) 206 (87·7%)
Other 0 2 (1·8%) 0 2 (0·9%)
HCV genotype
1a 10 (90·9%) 53 (47·7%) 59 (52·2%) 122 (51·9%)
1b 1 (9·1%) 58 (52·3%) 53 (46·9%) 112 (47·7%)
1 other 0 0 1 (0·9%) 1 (0·4%)
IL28B
CC 2 (18·2%) 30 (27·0%) 30 (26·5%) 62 (26·4%)
Non-CC 9 (81·8%) 79 (71·2%) 83 (73·5%) 171 (72·8%)
Missing 0 2 (1·8%) 0 2 (0·9%)
Cirrhosis
No 11 (100·0%) 104 (93·7%) 106 (93·8%) 221 (94·0%)
Yes 0 7 (6·2%) 7 (6·2%) 14 (6·0%)
Hepatitis fibrosis stage
F0–F2 11 (100%) 76 (68·5%) 76 (67·3%) 163 (69·4%)
F3 0 13 (11·7%) 15 (13·3%) 28 (11·9%)
F4 0 7 (6·3%) 7 (6·2%) 14 (6·0%)
Other* 0 15 (13·5%) 15 (13·3%) 30 (12·8%)
Baseline HCV RNA
≤800 000 IU/mL 3 (27·3%) 50 (45·0%) 47 (41·6%) 100 (42·6%)
>800 000 IU/mL 8 (72·7%) 61 (55·0%) 66 (58·4%) 135 (57·4%)
HCV treatment history
Naive 10 (90·9%) 91 (82·0%) 88 (77·9%) 189 (80·4%)
Experienced 1 (9·1%) 20 (18·0%) 25 (22·1%) 46 (19·6%)
Dialysis status
On dialysis 6 (54·5%) 86 (77·5%) 87 (77·0%) 179 (76·2%)
Not on dialysis 5 (45·5%) 25 (22·5%) 26 (23·0%) 56 (23·8%)
Diabetes status
Diabetes 6 (54·5%) 38 (34·2%) 36 (31·9%) 80 (34·0%)
No diabetes 5 (45·5%) 73 (65·8%) 77 (68·1%) 155 (66·0%)
Chronic kidney disease stage
4 4 (36·4%) 18 (16·2%) 22 (19·5%) 44 (18·7%)
5 7 (63·6%) 93 (83·8%) 91 (80·5%) 191 (81·3%)
(Table 1 continues on next page)
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of drug, died, or discontinued from the study early for 
reasons unrelated to hepatitis C treatment. A secondary 
analysis including all patients who received at least 
one dose of study drug (full analysis set) was also done.
Target enrolment was 105 patients in each of the 
immediate treatment group and deferred treatment 
group, and 10 patients in the intensive pharmacokinetic 
cohort. With this sample size, there is 95% or more 
power to show that the SVR12 rate in patients receiving 
grazoprevir and elbasvir is higher than the reference 
SVR12 rate of 45%, at an overall one-sided 0·025 α level, 
if the true SVR12 rate of grazoprevir and elbasvir is about 
65%. A post-hoc descriptive summary of SVR4 (at 
week 16) in patients receiving placebo in the deferred 
treatment group is also reported. SVR12 cannot be 
reported for the deferred treatment group because these 
patients began active treatment at week 16.
The full analysis set population was used for the 
analysis of safety data. Tier 1 event rates were compared 
between immediate treatment and deferred treatment 
groups: p values and 95% CIs were calculated using the 
stratified Miettinen and Nurminen method with baseline 
dialysis status as the strata.22 Safety events occurring up 
to 14 days after completion of treatment were captured to 
ensure the reporting of events that might be related 
to persistence of study drug. The study is registered at 
ClinicalTrials.gov, number NCT02092350.
Role of the funding source
Merck Sharp & Dohme Corp contributed to trial 
management, data collection, statistical analyses, writing, 
and review of the report. All authors had access to the 
data, reviewed and approved the final report, and take 
full responsibility for the veracity of the data and 
statistical analysis. The corresponding author had full 
access to the data and had final responsibility for the 
decision to submit for publication.
Results
In total, 237 patients were enrolled and 235 received one 
or more doses of study drug between March 30, 2014, and 
Nov 28, 2014. Of these, 224 were assigned to the immediate 
treatment group (n=111) or deferred treatment group 
(n=113), and an additional 11 patients were assigned to the 
intensive pharmacokinetic treatment group (figure 1).
Demographic and baseline characteristics were 
generally balanced between the immediate treatment 
group, intensive pharmacokinetic, and deferred treatment 
group populations (table 1). Overall, 179 (76%) of 
235 patients were on haemodialysis and 191 (81%) had 
chronic kidney disease stage 5 at baseline. 80 (34%) 
patients had diabetes, 96 (41%) had cardiovascular disease, 
122 (52%) had HCV genotype 1a infection, 189 (80%) were 
HCV treatment-naive, and 14 (6%) were cirrhotic.
Of the 122 patients in the immediate treatment and 
intensive pharmacokinetic population, six were excluded 
from the modified full analysis set population for reasons 
other than virological failure (death, lost to follow-up, non-
compliance, patient withdrawal, and withdrawal by 
physician due to violent behaviour; figure 1). All 














(Continued from previous page)
Previous renal transplant
Yes 2 (18·2%) 15 (13·5%) 28 (24·8%) 45 (19·1%)
No 9 (81·8%) 96 (86·5%) 85 (75·2%) 190 (80·9%)
Primary aetiology of renal disease
Hypertension 4 (36·4%) 46 (41·4%) 42 (37·2%) 92 (39·1%)
Type 1 diabetes 2 (18·2%) 4 (3·6%) 7 (6·2%) 13 (5·5%)
Type 2 diabetes 2 (18·2%) 19 (17·1%) 25 (22·1%) 46 (19·6%)
Congenital cystic 
kidney disease




0 11 (9·9%) 5 (4·4%) 16 (6·8%)
Pyelonephritis 0 2 (1·8%) 0 2 (0·9%)
Urinary tract 
obstruction
0 4 (3·6%) 2 (1·8%) 6 (2·6%)
Cryoglobulinaemia 2 (18·2%) 2 (1·8%) 0 4 (1·7%)
Other 1 (9·1%) 19 (17·1%) 31 (27·4%) 51 (21·7%)
Data are n (%) or mean (SD). IL28B=interleukin 28B gene. *Other category applies to 30 patients assessed by Fibrotest 
but could not be considered cirrhotic.
Table 1: Patient demographics
Grazoprevir and elbasvir 
immediate treatment group and 
pharmacokinetic population
Grazoprevir and elbasvir 
deferred treatment group
SVR12 (HCV RNA<LLoQ)
Modified full analysis set 115/116 (99·1% [95·3–100·0]) ··
Full analysis set 115/122 (94·3% [88·5–97·7]) ··
On-treatment and follow-up virological response (mFAS, TND)*
Treatment week 2 51/122 (41·8%) 0/113
Treatment week 4 94/121 (77·7%) 1/113 (0·9%)
Treatment week 12 119/119 (100%) 1/113 (0·9%)
Follow-up week 4 117/118 (99·2%) 1/113 (0·9%)
On-treatment virological response (mFAS<LLoQ)*
Treatment week 2 81/122 (66·4%) 0/113
Treatment week 4 109/121 (90·1%) 2/113† (1·8%)
Treatment week 12 119/119 (100%) 1/113 (0·9%)
Follow-up week 4 118/118 (100%) 1/113 (0·9%)
Relapse (mFAS) 1/116 (0·9%) ··
Data are n/N (SVR% [95% CI]) or n/N (SVR%). The 95% CI was estimated based on the Clopper-Pearson method. 
SVR=sustained virological response. HCV=hepatitis C virus. LLoQ=lower limit of quantification (HCV RNA is detected 
but <15 IU/mL). mFAS=modified full analysis set. TND=HCV RNA target not detected (no calculated HCV RNA result 
obtained (ie, HCV RNA undetectable). *Modified full analysis set was not defined for the deferred treatment group so 
data are presented for the full analysis set population (all patients who received one or more doses of study drug). 
†In the deferred treatment group, two patients had HCV RNA <LLoQ at treatment week 4; one patient had 
undetectable HCV RNA and one patient had detectable but unquantifiable HCV RNA.
Table 2: Virological response
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discontinuation. Of the 116 remaining patients (immediate 
treatment group, n=105; intensive pharmacokinetic 
group, n=11), 115 (99%) achieved SVR12, a rate better than 
the historical control rate of 45% (p<0·001). One non-
cirrhotic patient with HCV genotype 1b infection and 
chronic kidney disease stage 5 relapsed 12 weeks after the 
end of treatment (table 2).
In the full analysis set population, 115 (94%) of 
122 patients achieved SVR12. Of the seven patients who 
did not achieve SVR12, six patients discontinued the 
study for reasons other than virological failure and one 
patient relapsed.
High response rates were observed in all subgroups 
(figure 2), including haemodialysis and non-haemodialysis, 
and those with characteristics historically associated with 
poor response to HCV therapy. In particular, SVR12 was 
achieved in 51 (100%) of 51 African American patients, 
86 (99%) of 87 patients with the IL28B non-CC genotype, 
40 (98%) of 41 patients with diabetes, and all six patients 
with cirrhosis.
The SVR4 rate in patients receiving placebo in the 
deferred treatment group was one (<1%) of 113. HCV 
RNA was undetectable in one patient receiving placebo 
4 weeks after the end of the placebo treatment period. 
This patient denied taking any HCV therapy outside the 
study, had not initiated deferred active therapy, and it was 
confirmed that the study drug dispensed during the 
treatment period was placebo.
Baseline NS3/4A or NS5A resistance-associated 
variants were detected in 36 (32·1%) of 112 and 17 (14·8%) 
of 115 patients in the immediate treatment group and 
intensive pharmacokinetic population with sequencing 
data, respectively (based on population sequencing). 
SVR12 was achieved in 36 (100%) of 36 and 16 (94·1%) of 
17 of these patients, respectively. The patient who 
relapsed had an NS5A L31M mutation at baseline.
The frequencies of adverse events were comparable 
between the immediate treatment and deferred treatment 
groups (76% vs 84%; table 3), and most adverse events 
were of mild or moderate intensity in both treatment 
groups. The most common adverse events 
(≥10% frequency) were headache, nausea, and fatigue 
and were comparable in the two groups. Cardiac serious 
adverse events were reported in two patients in the 
immediate treatment group (one cardiac arrest, one 
myocardial infarction) and three in the deferred 
treatment group (two myocardial infarctions, one 
cardiomyopathy; appendix). Two cases of congestive 
heart failure occurred in the immediate treatment group 
within 14 days of the end of treatment; one of these, 
judged by the investigator to be drug-related, was 
reported 6 weeks after study treatment ended. A total of 
16 (14%) patients in the immediate treatment group and 
19 (17%) patients in the deferred treatment group 
reported a serious adverse event during treatment or 
within 14 days after the end of treatment (appendix). The 
serious adverse events reported were consistent with the 
underlying co morbidities and complications within this 
patient population. The only serious adverse events 
reported in more than one patient in the immediate 
treatment group were hypertension and pneumonia (n=2 
each). There were no serious adverse events considered 
to be drug-related in the immediate treatment group.
In the deferred treatment group, serious adverse events 
reported in more than one patient were upper 
gastrointestinal haemorrhage (n=2), myocardial infarction 
(n=2), and aortic aneurysm (n=2). Increased lipase was 
the only serious drug-related adverse event in the deferred 
treatment group.
There were no discontinuations due to an adverse 
event in the immediate treatment group versus 
five patients in the deferred treatment group (one each 
Figure 2: SVR12 subgroup analyses (modified full analysis set)
SVR=sustained virological response. m=number of patients included in the analysis. n=number of patients who 
achieved SVR12 (HCV RNA <LLoQ [<15 IU/mL]) at 12 weeks after end of treatment. *Based on the Clopper-Pearson 
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of abdominal pain, elevated ALT and AST, atrial 
fibrillation with myocardial infarction, increased lipase, 
and acute myocardial infarction). There were four deaths, 
none considered related to study drug, during the initial 
treatment plus 14 day period. One (1%) patient in the 
immediate treatment group died from cardiac arrest and 
three (3%) in the deferred treatment group died 
from aortic aneurysm, pneumonia, and unknown cause 
of death.
The frequencies and severities of liver function 
measures were comparable between the immediate 
treatment and deferred treatment groups (table 3). Rises 
in ALT and AST were more common among patients 
receiving placebo than grazoprevir and elbasvir. Rises in 
bilirubin and alkaline phosphatase and change in blood 
urea nitrogen from baseline were comparable in both 
treatment groups (appendix). A higher frequency of 
low haemoglobin (8·5–<10·0 g/dL) was noted in the 
immediate treatment group (n=27, 24·3%) than in the 
deferred treatment group (n=19, 16·8%). Erythropoietin 
stimulating agents were used during the treatment 
period by 27 (24%) patients in the immediate treatment 
group and 34 (30%) patients in the deferred treat-
ment group. No adverse events suggestive of liver decom-
pensation were reported.
The frequencies of renal system adverse events were 
generally comparable between treatment groups 
(appendix). Two patients in the immediate treatment 
group initiated maintenance dialysis during the study 
and six patients (immediate treatment group, n=4; 
deferred treatment group, n=2) not on dialysis at baseline 
had a change in chronic kidney disease stage, based on a 
decrease in eGFR from 15–29 mL/min per 1·73m² at 
baseline to less than 15 mL/min per 1·73m². Worsening 
of proteinuria was reported in four patients in the 
immediate treatment group (dialysis, n=1; no dialysis, 
n=3) and eight patients in the deferred treatment group 
(dialysis, n=4; no dialysis, n=4). There was no consistent 
change in mean eGFR or creatinine in either treatment 
group (appendix).
Discussion
This study shows that the combination of grazoprevir 
and elbasvir for 12 weeks is an effective treatment 
regimen for patients with HCV genotype 1 infection and 
advanced stage 4–5 chronic kidney disease, including 
patients on haemodialysis and those considered difficult 
to treat with interferon-based antiviral therapy. Only one 
(<1%) of 116 patients who completed treatment with 
grazoprevir and elbasvir did not achieve SVR12. This 
non-cirrhotic patient with a NS5A L31M mutation at 
baseline relapsed after having undetectable HCV RNA at 
the end of treatment and at the 4-week post-treatment 
visit. No patient had on-treatment virological break-
through. The short, 12-week duration of treatment with 
grazoprevir and elbasvir might allow waitlisting of 
patients for kidney transplant while on treatment for 
HCV infection, a practice that was previously difficult 
due to the 24–48 weeks of treatment needed with 
peginterferon and ribavirin regimens.
The deferred treatment group was used to provide a 
comparator for safety data collected in the immediate 
treatment group, given the substantial comorbidities 
seen in patients with stage 4–5 chronic kidney disease. 
The safety profiles of patients who received grazoprevir 
and elbasvir and placebo treatment were comparable, 
with similar frequencies of adverse events, serious 
adverse events, and renal and hepatic laboratory 
Grazoprevir and elbasvir 
immediate treatment group 
(n=111)
Grazoprevir and elbasvir 
deferred treatment group 
(n=113)
Any adverse event*† 84 (75·7%) 95 (84·1%)
Headache 19 (17·1%) 19 (16·8%)
Nausea 17 (15·3%) 18 (15·9%)
Fatigue 11 (9·9%) 17 (15·0%)
Insomnia 7 (6·3%) 12 (10·6%)
Dizziness 6 (5·4%) 18 (15·9%)
Diarrhoea 6 (5·4%) 15 (13·3%)
Drug-related adverse event† 38 (34·2%) 39 (34·5%)
Serious adverse event† 16 (14·4%) 19 (16·8%)
Drug-related serious adverse event† 0 1 (0·9%)
Discontinuation due to an adverse event 0 5‡ (4·4%)
Deaths 1 (0·8%) 3 (2·7%)
Lowest haemoglobin on treatment§
8·5–10·0 g/dL 27 (24·3%) 19 (16·8%)
<8·5 g/dL 5 (4·5%) 5 (4·4%)
Alanine aminotransferase§
1·1–2·5 × baseline 2 (1·8%) 36 (31·9%)
>2·5 × baseline 1 (0·8%) 6 (5·3%)
>5·0 × baseline 0 1 (0·9%)
Aspartate aminotransferase§
1·1–2·5 × baseline 4 (3·6%) 38 (33·6%)
>2·5 × baseline 0 4 (4·6%)
>5·0 × baseline 0 0
Bilirubin§
>2·5–5·0 × baseline 1 (0·9%) 3 (2·7%)
>5·0–10·0 × baseline 0 0
>10·0 × baseline 0 0
Alkaline phosphatase§
1·1–2·5 × baseline 42 (37·8%) 36 (31·9%)
>2·5 × baseline 0 0
>5·0 × baseline 0 0
Creatinine§ >2·5 × baseline 1 (1·2%) 0
Change in blood urea nitrogen (mg/L) from 
baseline at treatment week 12§¶
–1·5 (3·6) 0·9 (2·6)
Data are n (%) or mean (SE). *Incidence 10% or more in one or more treatment groups during the initial treatment period 
and for 14 days after the completion of treatment (all patients as treated). †Number of patients with the specific adverse 
event. ‡Abdominal pain, elevated alanine transaminase and aspartate transaminase, acute myocardial infarction, atrial 
fibrillation with myocardial infarction, and increased lipase. §Data presented for patients with more than 1·0 change from 
baseline. ¶Patients not on dialysis at baseline (immediate treatment group, n=25; deferred treatment group, n=24).
Table 3: Safety and adverse events (initial treatment period and first 14 days after completion of treatment)
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abnormalities. No patient discontinued due to an adverse 
event in the immediate treatment group. Previous 
studies of first-generation HCV protease inhibitors have 
shown a reversible decline in eGFR during treatment;23 
however, no such changes were noted in the present 
study, and no differences in renal function were noted 
between treatment groups. The five patients with cardiac 
serious adverse events reflect the known high prevalence 
of hypertension, diabetes, and cardiovascular disease in 
patients with chronic kidney disease, especially those 
on haemodialysis.
SVR12 response rates in the present study are 
consistent with those reported in studies of patients 
with HCV genotype 1 infection and normal renal 
function. In the C-WORTHY study, a 12-week regimen 
of grazoprevir and elbasvir resulted in SVR12 in 98% of 
non-cirrhotic and 97% of cirrhotic patients.11,12 High 
response rates with grazoprevir and elbasvir have also 
recently been reported in patients with HCV infection 
and normal renal function with previous non-response 
to first-generation direct-acting antiviral agents and in 
treatment-naive patients.13,14 Efficacy in the present 
study was also generally comparable with that of a 
12-week regimen of sofosbuvir plus ledipasvir that 
achieved an SVR12 rate of 96–99% in non-cirrhotic and 
94% in cirrhotic treatment-naive patients with HCV 
genotype 1 infection and without chronic kidney disease 
stage 4–5.24,25
There are limitations to the present study. Patient 
numbers in some subgroups were small. Only 14 (6%) 
cirrhotic patients were included. Also, patients with 
decompensated liver disease and those receiving 
peritoneal dialysis were excluded. The results of the 
C-SURFER study therefore cannot be generalised to 
all patient subgroups. A recent study including 
205 Taiwanese haemodialysis patients with genotype 1b 
HCV infection reported an SVR rate of 64%.26 These data 
suggest that an SVR rate higher than our historical 
control rate of 45% is achievable in Taiwanese patients 
with HCV genotype 1b infection on haemodialysis and 
receiving peginterferon plus ribavirin for 48 weeks. Their 
result could be an overestimate of the treatment response 
since their study population was all Asian and thus a 
high percentage carried the IL28B CC genotype which is 
strongly predictive of SVR. Finally, the present study did 
not have an active comparator because of the restricted 
treatment options available for HCV infection in patients 
with advanced chronic kidney disease.
In conclusion, the results from the C-SURFER study 
suggest that a once-daily oral regimen of grazoprevir and 
elbasvir for 12 weeks has an acceptable safety profile and 
can achieve high rates of SVR in patients with HCV 
genotype 1 infection and advanced chronic kidney 
disease. The results of this study show that the efficacy 
and safety profile of this combination is consistent across 
many patient subgroups, including those receiving 
haemodialysis.
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Supplementary Materials 563 
Sample Size Considerations 564 
Several considerations led us to choose a reference SVR of 45% for this study: 565 
(1) Interferon (IFN) mono-therapy is recommended for HCV-infected patients with CKD stages566 
3–5 who are on or not yet on maintenance dialysis therapy. The meta-analyses, conducted by 567 
Fabrizi et al, revealed a summary SVR24 of 39% (CI 32–46%).
1
568 
(2) Given the substantial variation in the G1 proportion of the studies (ranging from 0 to 1) in the569 
Fabrizi meta-analyses, a bayesian logistic regression model for SVR was used to account for the 570 
variation of G1 proportions. Twenty studies with G1 proportion were identified from the Fabrizi 571 
paper and included in the re-analysis. Non-informative priors were used for the bayesian 572 
random-effect model containing a random intercept and a fixed effect of G1 proportion. The 573 
model predicts that, if the studies had enrolled 100% G1, the posterior probability/confidence 574 
that the true overall population mean for SVR rate would have been at most 45% is about 0.90. 575 
(3) A SVR of approximately 40% was observed in a large study of peginterferon/ribavirin in576 
3,070 HCV G1-infected patients without renal disease conducted in the United States.
23
 The 577 
SVR response of patients with CKD stage 4/5 is not expected to be higher than that of the 578 
general HCV population without renal disease. 579 
580 
39 
Supplementary Figure 1. Study Design. 
*Deferred open-label treatment arm (all randomised patients remained blinded to treatment until
FW4). 
GZR and EBR were administered as separate entities in the immediate and PK arms, and as a 
fixed dose-combination in the deferred arm. R = randomised 
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Supplementary Table 1. Serious adverse events (initial treatment period and first 14 follow-up days; full analysis set) 
Intensive PK arm:  
GZR 100mg + EBR 50mg 
for 12 Weeks 
Immediate treatment arm: 
GZR 100mg + EBR 50mg 
for 12 Weeks 
Deferred treatment arm: 
GZR Placebo + EBR 
Placebo for 12 Weeks 
Immediate + Intensive PK 
arms: GZR 100mg + EBR 
50mg for 12 Weeks 
n (%) n (%) n (%) n (%) 
Subjects in population 11 111 113 122 
with one or more adverse events 0 (0.0) 16 (14.4) 19 (16.8) 16 (13.1) 
with no adverse events 11 (100.0) 95 (85.6) 94 (83.2) 106 (86.9) 
Cardiac disorders 0 (0.0) 2 (1.8) 3 (2.7) 2 (1.6) 
Acute myocardial infarction 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Angina unstable 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Atrial fibrillation 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Cardiac arrest 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Cardiomyopathy 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Myocardial infarction 0 (0.0) 1 (0.9) 1 (0.9) 1 (0.8) 
Gastrointestinal disorders 0 (0.0) 2 (1.8) 4 (3.5) 2 (1.6) 
Diarrhoea 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Gastritis 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Localised intraabdominal fluid 
collection 
0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Pancreatitis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Upper gastrointestinal 
haemorrhage  
0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 
General disorders and 
administration site conditions 
0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Death 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Infections and infestations 0 (0.0) 5 (4.5) 3 (2.7) 5 (4.1) 
Abscess limb 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Appendicitis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Citrobacter sepsis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Enterobacter sepsis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Haematoma infection 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Infected fistula 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Osteomyelitis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Pneumonia 0 (0.0 2 (1.8) 1 (0.9) 2 (1.6) 
41 
Injury, poisoning and 
procedural complications 
0 (0.0) 1 (0.9) 2 (1.8) 1 (0.8) 
Arteriovenous fistula aneurysm 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Dialysis related complication 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Postoperative fever 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Procedural pain 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Investigations 0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 
Blood alkaline phosphatase 
increased 
0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Lipase increased 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Metabolism and nutrition 
disorder 
0 (0.0) 2 (1.8) 3 (2.7) 2 (1.6) 
Dehydration 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Fluid overload 0 (0.0) 1 (0.9) 1 (0.9) 1 (0.8) 
Hyperglycaemia 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Hyperkalaemia 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Musculoskeletal and 
connective tissue disorders 
0 (0.0) 1 (0.9) 1 (0.9) 1 (0.8) 
Intervertebral disc protrusion 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Myositis 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Neoplasms benign, malignant 
and unspecified (incl cysts and 
polyps) 
0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Prostate cancer 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Nervous system disorders 0 (0.0) 1 (0.9) 3 (2.7) 1 (0.8) 
Depressed level of 
consciousness 
0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Dizziness 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Headache 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Presyncope 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Renal and urinary disorders 0 (0.0) 0 (0.0) 1 (0.9 0 (0.0) 
Renal failure chronic 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Respiratory, thoracic and 
mediastinal disorders  
0 (0.0) 2 (1.8) 1 (0.9) 2 (1.6) 
Acute respiratory failure 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Pleural effusion 0 (0.0) 1 (0.9) 1 (0.9) 1 (0.8) 
Vascular disorders 0 (0.0) 4 (3.6) 5 (4.4) 4 (3.3) 
Aortic aneurysm 0 (0.0) 0 (0.0) 2 (1.8) 0 (0.0) 
Extremity necrosis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
42 
Hypertension 0 (0.0) 2 (1.8) 1 (0.9) 2 (1.6) 
Hypertensive crisis 0 (0.0) 1 (0.9) 0 (0.0) 1 (0.8) 
Orthostatic hypotension 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Peripheral venous disease 0 (0.0) 0 (0.0) 1 (0.9) 0 (0.0) 
Every subject is counted a single time for each applicable row and column. 
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Supplementary Table 2. Liver function tests 
Intensive PK arm: GZR 
100 mg + EBR 50 mg for 
12 Weeks  
Immediate treatment arm: 
GZR 100 mg + EBR 
50 mg for 12 Weeks 
Deferred treatment arm: 
GZR Placebo + EBR 
Placebo for 12 Weeks  
Immediate + Intensive PK 
arms: GZR 100 mg + EBR 
50 mg for 12 Weeks  
(N=11)  (N=111)  (N=113)  (N=122)  
Test Name (Unit) Criterion†  n/m  (%) n/m  (%) n/m  (%) n/m  (%) 
 CHEMISTRY  
 Alanine aminotransferase (IU/L)  Grade 1: 1·25–2·5× ULN  0/11  (0·0)  3/111  (2·7)  25/113 (22·1)  3/122  (2·5)  
 Range: 10-33 IU/L (females)  Grade 2: 2·6–5·0× ULN    0/11  (0·0)  1/111  (0·9)  3/113  (2·7)  1/122  (0·8)  
10-40 IU/L (males)   Grade 3: 5·1–10·0× ULN  0/11  (0·0)  0/111  (0·0)  2/113  (1·8)  0/122  (0·0)  
Grade 4: >10·0× ULN     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
1·1–2·5× Baseline     0/11  (0·0)  2/111  (1·8)  36/113 (31·9)  2/122  (1·6)  
>2·5–5·0× Baseline 0/11  (0·0)  1/111  (0·9)  6/113  (5·3)  1/122  (0·8)  
>5·0× Baseline 0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
 Aspartate aminotransferase (IU/L)  Grade 1: 1·25–2·5× ULN  0/11  (0·0)  2/111  (1·8)  21/113 (18·6)  2/122  (1·6)  
     Range: 10-36 IU/L (females)      Grade 2: 2·6–5·0× ULN    0/11  (0·0)  0/111  (0·0)  2/113  (1·8)  0/122  (0·0)  
10-43 IU/L (males)   Grade 3: 5·1–10·0× ULN  0/11  (0·0)  0/111  (0·0)  2/113  (1·8)  0/122  (0·0)  
Grade 4: >10·0× ULN     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
1·1–2·5× Baseline     0/11  (0·0)  4/111  (3·6)  38/113 (33·6)  4/122  (3·3)  
>2·5–5·0× Baseline 0/11  (0·0)  0/111  (0·0)  4/113  (3·5)  0/122  (0·0)  
>5·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
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 Bilirubin (mg/dL)  Grade 1: 1·1–1·5× ULN  0/11  (0·0)  1/111  (0·9)  2/113  (1·8)  1/122  (0·8)  
 Range: 0.10-1.10 mg/dL   Grade 2: 1·6–2·5× ULN  0/11  (0·0)  0/111  (0·0)  2/113  (1·8)  0/122  (0·0)  
Grade 3: 2·6–5·0× ULN  0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
Grade 4: >5·0× ULN     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
>2·5–5·0× Baseline 0/11  (0·0)  1/111  (0·9)  3/113  (2·7)  1/122  (0·8)  
>5·0 -10·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
>10·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
†A subject was included in the highest applicable toxicity grade per test as determined by his/her worst post-baseline test result (for the specified study phase(s)) that was also worse than baseline.  For 
tests with additional non-graded criterion categories, a subject was also included in the highest applicable non-graded category as determined by his/her worst post-baseline abnormal test result for 
the specified study phase(s). 
 The baseline test result is the result from the latest sample before the start of study therapy. 
 N=Number of subjects randomly assigned in the treatment group. 
 n=Number of subjects with test results that met predetermined criteria and were worse than baseline. 
 m=Number of subjects with a baseline test result and at least one postbaseline result. 
 LLN=Lower limit of normal range.  ULN=Upper limit of normal range. 
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Supplementary Table 3. Laboratory safety summary 
Intensive PK arm: GZR 
100 mg + EBR 50 mg for 
12 Weeks  
Immediate treatment arm: 
GZR 100 mg + EBR 
50 mg for 12 Weeks 
Deferred treatment arm: 
GZR Placebo + EBR 
Placebo for 12 Weeks  
Immediate + Intensive PK 
arms: GZR 100 mg + EBR 
50 mg for 12 Weeks  
(N=11)  (N=111)  (N=113)  (N=122)  
Test Name (Unit) Criterion†  n/m  (%) n/m  (%) n/m  (%) n/m  (%) 
 CHEMISTRY  
 Albumin (gm/dL)  Grade 1: 3·0–<LLN     1/11  (9·1)  6/111  (5·4)  8/113  (7·1)  7/122  (5·7)  
    Range: 3.5-5.5 gm/dL   Grade 2: 2·0–2·9     0/11  (0·0)  3/111  (2·7)  5/113  (4·4)  3/122  (2·5)  
Grade 3: <2·0     0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
Grade 4: Not Applicable  0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
 Alkaline phosphatase (IU/L)  Grade 1: 1·25–2·5× ULN  0/11  (0·0)  27/111 (24·3)  23/113 (20·4)  27/122 (22·1)  
  Range: 30-115 IU/L (females)  Grade 2: 2·6–5·0× ULN    0/11  (0·0)  2/111  (1·8)  4/113  (3·5)  2/122  (1·6)  
43-115 IU/L (males)   Grade 3: 5·1–10·0× ULN  0/11  (0·0)  0/111  (0·0)  3/113  (2·7)  0/122  (0·0)  
Grade 4: >10·0× ULN     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
1·1–2·5× Baseline     2/11  (18·2)  42/111 (37·8)  36/113 (31·9)  44/122 (36·1)  
>2·5–5·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
>5·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
 Amylase (IU/L)  Grade 1: 1·1–1·5× ULN  5/11  (45·5)  29/111 (26·1)  29/113 (25·7)  34/122 (27·9)  
 Range: 35-121 IU/L   Grade 2: 1·6–2·0× ULN  3/11  (27·3)  21/111 (18·9)  17/113 (15·0)  24/122 (19·7)  
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Grade 3: 2·1–5·0× ULN  1/11  (9·1)  24/111 (21·6)  22/113 (19·5)  25/122 (20·5)  
Grade 4: >5·0× ULN     0/11  (0·0)  0/111  (0·0)  4/113  (3·5)  0/122  (0·0)  
 Creatine kinase (IU/L)  Grade 1: 3·0–5·9× ULN     1/11  (9·1)  6/111  (5·4)  2/113  (1·8)  7/122  (5·7)  
 Range: 24-169 IU/L (females)  Grade 2: 6·0–9·9× ULN     1/11  (9·1)  1/111  (0·9)  1/113  (0·9)  2/122  (1·6)  
 24-207 IU/L (males)   Grade 3: 10·0–19·9× ULN  1/11  (9·1)  0/111  (0·0)  1/113  (0·9)  1/122  (0·8)  
Grade 4: ≥20·0× ULN     0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
 Creatinine (mg/dL)  Grade 1: 1·1–1·3× ULN  0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
 Range: 0.7-1.4 mg/dL   Grade 2: 1·4–1·8× ULN  0/11  (0·0)  3/111  (2·7)  3/113  (2·7)  3/122  (2·5)  
Grade 3: 1·9–3·4× ULN  4/11  (36·4)  14/111 (12·6)  19/113 (16·8)  18/122 (14·8)  
Grade 4: ≥3·5× ULN     4/11  (36·4)  74/111 (66·7)  76/113 (67·3)  78/122 (63·9)  
>2·5× Baseline 0/11  (0·0)  1/111  (0·9)  0/113  (0·0)  1/122  (0·8)  
 Direct bilirubin (mg/dL)  Grade 1: 1·1–1·5× ULN  0/11  (0·0)  1/111  (0·9)  3/113  (2·7)  1/122  (0·8)  
  Range: 0.00-0.40 mg/dL           Grade 2: 1·6–2·5× ULN  0/11  (0·0)  0/111  (0·0)  3/113  (2·7)  0/122  (0·0)  
Grade 3: 2·6–5·0× ULN  0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
Grade 4: >5·0× ULN     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
>2·5–5·0× Baseline 0/11  (0·0)  0/111  (0·0)  2/113  (1·8)  0/122  (0·0)  
>5·0–10·0× Baseline 0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
>10·0× Baseline 0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
 Gamma glutamyl transferase (IU/L)  Grade 1: 1·1–2·5× ULN  0/11  (0·0)  8/111  (7·2)  33/113 (29·2)  8/122  (6·6)  
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 Range: 5-32 IU/L (females)           Grade 2: 2·6–5·0× ULN    0/11  (0·0)  3/111  (2·7)  8/113  (7·1)  3/122  (2·5)  
 10-49 IU/L (males)   Grade 3: 5·1–20·0× ULN  0/11  (0·0)  1/111  (0·9)  13/113 (11·5)  1/122  (0·8)  
Grade 4: >20·0× ULN     0/11  (0·0)  0/111  (0·0)  4/113  (3·5)  0/122  (0·0)  
 Triacylglycerol lipase (IU/L)  Grade 1: 1·1–1·5× ULN  0/11  (0·0)  25/111 (22·5)  17/113 (15·0)  25/122 (20·5)  
     Range: 13-60 IU/L           Grade 2: 1·6–3·0× ULN  6/11  (54·5)  40/111 (36·0)  41/113 (36·3)  46/122 (37·7)  
Grade 3: 3·1–5·0× ULN  1/11  (9·1)  10/111 (9·0)  15/113 (13·3)  11/122 (9·0)  
Grade 4: >5·0× ULN     0/11  (0·0)  9/111  (8·1)  4/113  (3·5)  9/122  (7·4)  
 COAGULATION  
 Prothrombin intl. normalized ratio  Grade 1: 1·1–1·5× ULN  1/11  (9·1)  16/111 (14·4)  7/113  (6·2)  17/122 (13·9)  
 Range: 0.9-1.1   Grade 2: 1·6–2·0× ULN  0/11  (0·0)  2/111  (1·8)  1/113  (0·9)  2/122  (1·6)  
Grade 3: 2·1–3·0× ULN  0/11  (0·0)  2/111  (1·8)  2/113  (1·8)  2/122  (1·6)  
Grade 4: >3·0× ULN     0/11  (0·0)  0/111  (0·0)  3/113  (2·7)  0/122  (0·0)  
>1·5× Baseline 0/11  (0·0)  6/111  (5·4)  7/113  (6·2)  6/122  (4·9)  
 HEMATOLOGY  
 Eosinophils/leukocytes (%)  > 5% and baseline <5% 5/11  (45·5)  21/111 (18·9)  20/108 (18·5)  26/122 (21·3)  
     Range:  0.0-7.0 %     > 5% and baseline ≥5% 0/11  (0·0)  19/111 (17·1)  14/108 (13·0)  19/122 (15·6)  
 Hemoglobin (g/dL)  Grade 1: 10·0–10·9  2/11  (18·2)  24/111 (21·6)  26/113 (23·0)  26/122 (21·3)  
  Range: 12.5-17.0 g/dL    Grade 2: 9·0–9·9     3/11  (27·3)  20/111 (18·0)  16/113 (14·2)  23/122 (18·9)  
48 
Grade 3: 7·0–8·9  1/11  (9·1)  11/111 (9·9)  6/113  (5·3)  12/122 (9·8)  
Grade 4: <7·0  0/11  (0·0)  1/111  (0·9)  2/113  (1·8)  1/122  (0·8)  
8·5–<10·0  3/11  (27·3)  27/111 (24·3)  19/113 (16·8)  30/122 (24·6)  
<8·5  1/11  (9·1)  5/111  (4·5)  5/113  (4·4)  6/122  (4·9)  
 Leukocytes (103/µL)  Grade 1: 2·0–2·5     0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
  Range: 3.5-12.5 x 103/µL   Grade 2: 1·5–1·999  0/11  (0·0)  0/111  (0·0)  1/113  (0·9)  0/122  (0·0)  
Grade 3: 1·0–1·499  0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
Grade 4: <1·0     0/11  (0·0)  0/111  (0·0)  0/113  (0·0)  0/122  (0·0)  
 Lymphocytes (103/µL)  Grade 1: 0·60–0·65    0/11  (0·0)  5/111  (4·5)  4/109  (3·7)  5/122  (4·1)  
  Range: 0.9-3.6 x 103/µL   Grade 2: 0·50–0·599  0/11  (0·0)  2/111  (1·8)  4/109  (3·7)  2/122  (1·6)  
Grade 3: 0·35–0·499  0/11  (0·0)  0/111  (0·0)  0/109  (0·0)  0/122  (0·0)  
Grade 4: <0·35     0/11  (0·0)  0/111  (0·0)  0/109  (0·0)  0/122  (0·0)  
 Neutrophils (103/µL)  Grade 1: 1·00–1·3     0/11  (0·0)  1/111  (0·9)  2/109  (1·8)  1/122  (0·8)  
  Range: 1.7-7.9 x 103/µL   Grade 2: 0·75–0·999  0/11  (0·0)  1/111  (0·9)  1/109  (0·9)  1/122  (0·8)  
Grade 3: 0·50–0·749  0/11  (0·0)  0/111  (0·0)  1/109  (0·9)  0/122  (0·0)  
Grade 4: <0·50     0/11  (0·0)  0/111  (0·0)  0/109  (0·0)  0/122  (0·0)  
 Platelet (103/µL)  Grade 1: 100–124·999  2/11  (18·2)  10/110 (9·1)  15/113 (13·3)  12/121 (9·9)  
 Range: 125-375 x 103/µL   Grade 2: 50–99·999     0/11  (0·0)  8/110  (7·3)  12/113 (10·6)  8/121  (6·6)  
Grade 3: 25–49·999     0/11  (0·0)  0/110  (0·0)  0/113  (0·0)  0/121  (0·0)  
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Grade 4: <25 0/11  (0·0)  0/110  (0·0)  0/113  (0·0)  0/121  (0·0)  
†A subject was included in the highest applicable toxicity grade per test as determined by his/her worst post-baseline test result (for the specified study phase(s)) that was also worse than baseline.  For 
tests with additional non-graded criterion categories, a subject was also included in the highest applicable non-graded category as determined by his/her worst post-baseline abnormal test result for 
the specified study phase(s). 
 The baseline test result is the result from the latest sample before the start of study therapy. 
 N=Number of subjects randomly assigned in the treatment group. 
 n=Number of subjects with test results that met predetermined criteria and were worse than baseline. 
 m=Number of subjects with a baseline test result and at least one postbaseline result. 
 LLN=Lower limit of normal range.  ULN=Upper limit of normal range. 
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Supplementary Table 4. Special Renal Function Monitored Adverse Events 
Dialysis status  Immediate arm: 
GZR 100 mg + 
EBR 50 mg for 
12 Weeks 
Deferred arm: 
GZR Placebo + 
EBR Placebo for 
12 Weeks 
Difference in % 
Immediate – Deferred 
at baseline  n  (%)  n  (%)  Estimate (95% CI)†  
 Subjects in population  Overall  111 113  
On Dialysis  86 87  
Not On Dialysis  25 26  
 Renal function monitor event‡ Overall  6 (5·4)  2 (1·8)  3·7 (-1·2, 10·4)  
   Increasing dialysis frequency     On Dialysis  0 (0·0)  0 (0·0)  0·0 (-4·3, 4·3)  
   Initiation of maintenance dialysis  Not On Dialysis  2 (8·0)  0 (0·0)  8·0 (-5·6, 25·2)  
   Increase in CKD stages§      Not On Dialysis  4 (16·0)  2 (7·7)  8·3 (-11·1, 28·6)  
 Number of subjects had baseline and 
post-baseline urine protein test 
Overall  49 50  
On Dialysis  25 26  
Not On Dialysis  24 24  
 Worsening of proteinuria║  Overall  4 (8·2)  8 (16·0)  -7·9 (-21·8, 5·6) 
On Dialysis  1 (4·0)  4 (15·4)  -11·4 (-30·5, 6·6)
Not On Dialysis  3 (12·5)  4 (16·7)  -4·2 (-26·0, 17·6)
† Based on Miettinen & Nurminen method stratified by dialysis status at baseline; if no subjects are in one of the treatment groups  
involved in a comparison for a particular stratum, then that stratum is excluded from the treatment comparison. 
‡ A subject had renal function monitor event if any of the following criteria had occurred from the initiation of study therapy   
through 14 days following treatment: (1) increasing dialysis frequency in subjects who were on hemodialysis at baseline, (2)   
initiation of maintenance hemodialysis in subjects who were not on hemodialysis at baseline, or (3) the increase in CKD stages. 
§ For subject who was not on dialysis at baseline and did not initiate maintenance dialysis during the course of the trial, the
increase in CKD stages was determined by whether the subject had decrease of eGFR from CKD 4 category (15-29)   at baseline 
to CKD 5 category (<15) during the treatment.
║ Elevation of proteinuria is defined as any elevation of protein grade from baseline by 2 grades or more.
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Supplementary Table 5. Change from baseline in eGFR (mL/min/1·73m
2
) initial treatment
period through 4 weeks after end of treatment in patients not on dialysis at baseline (all subjects 
as treated)  
Immediate treatment arm: GZR 
100 mg + EBR 50 mg for 12 Weeks 
Deferred treatment arm: GZR Placebo 
+ EBR Placebo for 12 Weeks
Difference in Change 
from Baseline 
(Immediate – Deferred 
Arm)  
Visit Time Point N  Change from Baseline 
Mean (SD)  
N  Change from Baseline  
Mean (SD)  
Estimate (95% CI)  
 TW1  23     0·04 (2·06)   26 -1·54 (3·22)     1·58 (0·01, 3·16)  
 TW2  23     0·22 (3·55)   26 -1·31 (3·17)     1·53 (-0·41, 3·46)  
 TW3  23 -0·04 (4·49)  25 -1·04 (3·02)     1·00 (-1·21, 3·20)  
 TW4  24 -0·42 (2·21)  23 -1·30 (2·75)     0·89 (-0·57, 2·35)  
 TW6  25 -0·36 (5·75)  26 -2·08 (3·11)     1·72 (-0·87, 4·30)  
 TW8  24     0·88 (4·85)   25 -1·52 (3·28)     2·40 (0·02, 4·77)  
 TW10  25 -0·24 (4·88)  25 -0·80 (3·15)     0·56 (-1·77, 2·89)  
 TW12  25 -0·32 (4·65)  24 -1·08 (3·83)     0·76 (-1·69, 3·22)  
 FW4  24 -0·13 (4·79)  24 -1·13 (4·85)     1·00 (-1·80, 3·80)  
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Supplementary Table 6. Change from baseline in serum creatinine (mg/dL) initial treatment 
period through 4 weeks after end of treatment in subjects not on dialysis at baseline (all subjects 
as treated) 
Immediate treatment arm: GZR 
100 mg + EBR 50 mg for 12 Weeks 
Deferred treatment arm: GZR Placebo 
+ EBR Placebo for 12 Weeks
Difference in Change 
from Baseline 
(Immediate – Deferred 
Arm)  
Visit Time Point N  Change from Baseline 
Mean (SD)  
N  Change from Baseline 
Mean (SD)  
Estimate (95% CI)  
 TW1  23     0·02 (0·31)   26     0·12 (0·31)  -0·09 (-0·27, 0·08) 
 TW2  23 -0·04 (0·45)  26     0·05 (0·33)  -0·10 (-0·32, 0·13) 
 TW3  23     0·03 (0·58)   25     0·05 (0·36)  -0·03 (-0·31, 0·25) 
 TW4  24     0·05 (0·59)   23     0·10 (0·37)  -0·05 (-0·34, 0·24) 
 TW6  25     0·24 (1·09)   26     0·17 (0·37)      0·07 (-0·39, 0·52)  
 TW8  24 -0·19 (0·62)  25     0·10 (0·33)  -0·28 (-0·57, -0·00) 
 TW10  25     0·04 (0·85)   25     0·09 (0·34)  -0·04 (-0·41, 0·33) 
 TW12  25     0·07 (0·96)   24     0·13 (0·35)  -0·06 (-0·48, 0·36) 
 FW4  24     0·00 (1·01)   24     0·18 (0·46)  -0·18 (-0·64, 0·28) 
 N = Number of patients with results at baseline and the analysis time point. 
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1.0 TRIAL SUMMARY
Abbreviated Title MK-5172 in Combination with MK-8742 in subjects with HCV and 
Chronic Kidney Disease
Trial Phase Phase II/III
Clinical Indication Treatment of hepatitis C virus infection
Trial Type Interventional
Type of control Placebo
Route of administration Oral
Trial Blinding Double-blind
Treatment Groups Immediate Treatment: MK-5172 100 mg + MK-8742 50 mg for 12 
weeks
Deferred Treatment: MK-5172 placebo+ MK-8742 placebo for 12 
weeks + 4 weeks unblinding period follow-up followed by MK-5172 100 
mg + MK-8742 50 mg for 12 weeks
Intensive PK: MK-5172 100 mg + MK-8742 50 mg for 12 weeks (open-
label)
Number of trial subjects Approximately 220 subjects will be enrolled.
Estimated duration of trial The sponsor estimates that the trial will require approximately 3 months 
of enrollment (12 weeks) + up to 60 days of screening (8.5 weeks) + up 
to 24 weeks of treatment (active or placebo/active) + 4 week unblinding 
period (deferred treatment arm only) + 24 weeks of follow-up for a total 
of 72.5 weeks from the time the first subject signs the informed consent 
until the last subject’s last visit.
Duration of Participation Each subject will participate in the trial for approximately 44.5 or 60.5 
weeks (depending on the treatment arm) from the time the subject signs 
the Informed Consent Form (ICF) through the final contact depending on 
randomization.  After a screening phase of 60 days, each subject will be 
receiving assigned treatment for approximately 12 or 24 weeks.  After 
the end of treatment each subject will be followed for 24 weeks (deferred 
treatment arm will be followed for an additional 4 weeks post-placebo 
treatment).
A list of abbreviations used in this document can be found in Section 12.4.
2.0 TRIAL DESIGN
Trial Design2.1
This is a randomized, parallel-group, multi-site, placebo controlled trial of MK-5172 and 
MK-8742 in subjects with Hepatitis C and Chronic Kidney disease (CKD) to be conducted in 
conformance with Good Clinical Practices.  
The trial will enroll approximately 220 cirrhotic and non-cirrhotic, Genotype 1 (GT1), HCV 
patients who have chronic kidney disease (CKD). A definition of the HCV and CKD disease 
status for targeted subjects in this study is included in Table 1.  Patients on maintenance 
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hemodialysis (including subjects awaiting renal transplant and subjects with a previous failed 
kidney transplant no longer on immunosuppressant therapy) and patients with CKD stages 4-
5 who are not on hemodialysis will be enrolled with a minimum of 20% of patients in the 
latter category. Subjects must be either treatment naïve to all HCV treatments including any 
direct acting antivirals (DAA) or are intolerant or who have relapsed or were null-responders 
to a prior IFN-based treatment regimen.  Subjects are required to undergo liver biopsy or 
non-invasive test to determine the presence or absence of cirrhosis.  
Study subjects (210) will be randomized in a 1:1 ratio to receive MK-5172 100 mg QD and 
MK-8742 50 mg QD for 12 weeks with 24 weeks of follow-up after dosing is completed
(immediate treatment group) or 12 weeks of placebo to MK-5172 and MK-8742 followed by 
unblinding (after a 4 week unblinding period) and then 12 weeks of MK-5172 100 mg QD 
and MK-8742 50 mg QD for 12 weeks with 24 weeks of follow-up after dosing is completed
(deferred treatment group).
In addition, 10 subjects (5 on hemodialysis and 5 non-dialysis CKD) will be assigned to 
receive open-label MK-5172 100 mg QD and MK-8742 50 mg QD for 12 weeks with 24 
weeks of follow-up after dosing is completed. These 10 subjects will constitute the Intensive 
PK arm.
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Table 1 Definition of HCV and CKD in Target Subject Population
Hepatitis C Disease Status
Chronic HCV Genotype 1 infection
With or without evidence of cirrhosis 
Cirrhosis is defined as any one the following [44,41]: 
 A liver biopsy performed prior to Day 1 of this study showing cirrhosis (F4)
 Fibroscan performed within 12 calendar months of Day 1 of this study  showing cirrhosis
with result >12.5kPa [41]*
 A FibroSure® (Fibrotest®) performed during screening with a score of >0.75 and an
Aspartate Aminotransferase to Platelet Ratio Index (APRI) of >2.
Treatment naive to l anti-HCV treatment including any DAA
OR
Prior Treatment Relapsers: Subjects that have relapsed after completing a prior course of HCV therapy 
that included interferon (IFN or PEG-IFN + Ribavirin) but that did not include any licensed or 
investigational direct acting antiviral agents (DAAs)
OR 
P/R Partial responder: > 2 log10 IU/mL reduction in HCV RNA by week 12
of treatment, but HCV RNA quantifiable (≥ LLOQ) at the end of treatment.
OR
Null Responder:  Subjects had a <2 log10 IU/mL reduction in HCV RNA at Week 12 OR <1 log10 
IU/mL decline from baseline at Week 4 while on a prior course of HCV therapy that included IFN or 
PEG-IFN ± Ribavirin but that did not include any direct acting antivirals and discontinued therapy 
prior to Week 12
OR
Subjects who prematurely discontinued an IFN or PEG-IFN regimen± Ribavirin (that did not include 
any licensed or investigational DAAs) because of drug intolerance. 
Chronic Kidney Disease Status
CKD Stages 4-5: Subjects with eGFR (by the MDRD-4 ) ≤29 ml/min/1.73m2 who are not on dialysis
OR
CKD-5D: Subjects on hemodialysis (including subjects awaiting renal transplantation)
Administration of a 12 week regimen of MK-5172+MK-8742 regimen (without ribavirin) to 
treatment-naïve and treatment-experienced, cirrhotic and non-cirrhotic GT1 patients was 
highly efficacious in an ongoing PN035 trial (see Section 4.1.3).
Safety and tolerability will be carefully monitored throughout the study by the SPONSOR 
(or designee) in accordance with standard procedures and also by an external Data 
Monitoring Committee (eDMC).
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial Flow Chart - Section 6.0. Details of each 
procedure are provided in Section 7.0 – Trial Procedures.
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Trial Diagram2.2
The trial design is depicted in Figure 1.
Figure 1  Trial Design 
3.0 OBJECTIVE(S) & HYPOTHESIS(ES)
Primary Objective(s) & Hypothesis(es)3.1
In subjects who have chronic kidney disease (CKD Stages 4-5) and chronic HCV GT1 
infection with pre-treatment HCV RNA of at least 10,000 IU/mL:
The Primary Objective(s) are:
(1) Objective:  To evaluate the efficacy of MK-5172 + MK-8742 in HCV GT1 subjects with
chronic kidney disease (CKD) within the immediate treatment and the intensive PK
groups.
Hypothesis: The proportion of HCV GT1 infected CKD 4-5 subjects achieving SVR
(defined as HCV RNA <LLoQ (either TD(u) or TND) 12 weeks after the end of all study
therapy will be superior to 45% (see Section 4.2.1- Rationale for Study).
(2) Objective: To evaluate the safety and tolerability of MK-5172 in combination with MK-
8742 in the immediate treatment group relative to the placebo treatment of the deferred
treatment group.
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Secondary Objective(s) & Hypothesis(es)3.2
(1) Objective:  To evaluate the efficacy of MK-5172 in combination with MK-8742 as
assessed by the proportion of subjects achieving:
 SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy)
within the immediate treatment and the intensive PK groups, defined as HCV RNA
<LLoQ (either TD(u) or TND) 24 weeks after the end of all study therapy.
 SVR4 (Sustained Virologic Response 4 weeks after the end of all study therapy),
defined as HCV RNA <LLoQ (either TD(u) or TND) 4 weeks after the end of all
study therapy.
 SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy),
defined as HCV RNA <LLoQ (either TD(u) or TND) 12 weeks after the end of all
study therapy on active period of deferred treatment arm,
 SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy),
defined as HCV RNA <LLoQ (either TD(u) or TND) 12 weeks after the end of all
study therapy for all active treatment arms combined.
(2) Objective: To evaluate the safety and tolerability of MK-5172 in combination with MK-
8742 for all treatment arms.
(3) Objective:  To evaluate the emergence of viral resistance-associated variants (RAVs)
resistant to MK-5172 and MK-8742 when administered as part of a combination regimen.
Other Objectives (e.g., Tertiary, Exploratory, etc.)3.3
(1) Objective:  To evaluate the pharmacokinetics (PK) of MK-5172 and MK-8742.
(2) Objective: To evaluate the pharmacokinetic/pharmacodynamics (PK/PD) relationship
of MK-5172 and MK-8742 plasma levels to efficacy and safety.
(3) Objective: To evaluate biomarkers (e.g., proteins and metabolite production), that may
be predictive of tolerability of study drugs and virologic response to MK -5172 in
combination with MK-8742 by comparing biomarker levels over time in subjects who
respond or fail study therapy.
(4) Objective: To describe and compare changes from baseline in health-related quality of
life during and after active and placebo treatment periods.
(5) Objective:  To assess the genetic variation in the human IL28B gene as a predictor of
virologic response in each treatment arm.
(6) Objective:  To determine the impact of HCV treatment on cryoglobulinemia in the
patients with CKD.
03XKX6
Product:  MK-5172 17
Protocol/Amendment No.: 052-04 
MK-5172-052-04 Final Protocol 04-Jun-2014
4.0 BACKGROUND & RATIONALE
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5.0 METHODOLOGY
Entry Criteria5.1
5.1.1 Diagnosis/Condition for Entry into the Trial
Male/Female subjects with GT1 HCV who are cirrhotic or noncirrhotic and also have 
Chronic Kidney Disease who are at least 18 years of age will be enrolled in this trial.
5.1.2 Subject Inclusion Criteria
In order to be eligible for participation in this trial, the subject must:
1. Be ≥18 years of age on day of signing informed consent.
2. Have documented chronic (at least 6 months) HCV GT1 infection (with no evidence of
non typable or mixed genotypes) :
 Positive for anti-HCV antibody, HCV RNA, or an HCV genotype
 HCV RNA (≥ 10,000 IU/mL in peripheral blood)
3. Subjects with or without cirrhosis may be enrolled into this study.  All subjects must have
one of the below liver disease staging assessments as follows:
 Liver biopsy performed within 24 months of Day 1 (if subject is cirrhotic then there is
no time restriction on biopsy)
03XKX6
Redacted
Product:  MK-5172 30
Protocol/Amendment No.: 052-04 
MK-5172-052-04 Final Protocol 04-Jun-2014
 Fibroscan performed within 12 months of Day 1
 A FibroSure® (Fibrotest®) and Aspartate Aminotransferase to Platelet Ratio Index
(APRI) (APRI is automatically calculated by central laboratory) during Screening
In the absence of a definitive diagnosis of presence or absence of cirrhosis by the above 
critieria, a liver biopsy is required.  Liver biopsy results supersede the results obtained by 
Fibroscan or FibroSure®.
4. Have an HCV treatment status that is one of the following:
Treatment naïve: Naive to all anti-HCV treatment
Prior IFN or PEG-IFN + Ribavirin Treatment failures: Null responders, Partial
responders, Relapsers
P/R Intolerant:  Subjects were intolerant to a prior IFN or PEG-IFN ± Ribavirin regimen,
Subjects discontinued treatment prematurely and were therefore unable to complete a full
course of therapy because of  drug-related toxicity.
5. Have Chronic Kidney Disease defined as:
Subjects with GFR ≤29 who are non-dialysis dependent (NDD) or have been on
hemodialysis (HD) for at least 3 months (including subjects awaiting kidney transplant
and subjects with failed kidney transplants no longer on immunosuppressant therapy).
6. Agree (if subject is of reproductive potential) to remain truly abstinent or use (or have
their partner use) 2 acceptable methods of birth control from at least 2 weeks prior to Day
1 through 14 days after the last dose of study drugs, or longer if dictated by local
regulations.
If acceptable by local regulatory agencies, methods of birth control allowed in the study
are: intrauterine device (IUD), diaphragm with spermicide, hormonal contraceptives (e.g.,
birth control pills, transdermal patch, or injectables), contraceptive sponge, female
condom, male condom with spermicide or vasectomy.
Note: Periodic abstinence (e.g., abstinence only on certain calendar days, abstinence only
during ovulation period, use of symptothermal methods, use of post-ovulation methods
and withdrawal) are not acceptable methods of contraception.
7. A female subject who is not of reproductive potential is eligible without requiring the use
of contraception.  A female subjects who is not of reproductive potentials is  defined as
one who has either 1) reached natural menopause (defined as 12 months with no menses
without an alternative medical cause), 2) 6 weeks post surgical bilateral oophorectomy
with or without hysterectomy, or 3) bilateral tubal ligation.
8. A male subject who is not of reproductive potential is eligible without requiring the use of
contraception. A male subject who is not of reproductive potential is defined as: one who
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has undergone a successful vasectomy. A successful vasectomy is defined as: (1) 
microscopic documentation of azoospermia, or (2) a vasectomy more than 2 years ago 
with no resultant pregnancy despite sexual activity post vasectomy.
9. understand the study procedures, alternative treatments available, risks involved with the
study, and voluntarily agrees to participate by giving written informed consent.
10. The subject may also provide consent for Future Biomedical Research.  However, the
subject may participate in the main trial without participating in Future Biomedical
Research
5.1.3 Subject Exclusion Criteria
The subject must be excluded from participating in the trial if the subject:
1. Is under the age of legal consent, is mentally or legally incapacitated, has significant
emotional problems at the time of pre-study screening visit or expected during the
conduct of the study or has a history of a clinically significant psychiatric disorder which,
in the opinion of the investigator, would interfere with the study procedures.
2. Evidence of decompensated liver disease manifested by the presence of or history of
ascites, gastric or variceal bleeding, hepatic encephalopathy or other signs or symptoms
of advanced liver disease.
3. Is on peritoneal dialysis for management of Kidney disease
4. In the opinion of the investigator the subject has a high likelihood of receiving a renal
transplant during the study treatment period (up to 24 weeks from Day 1).
5. Is coinfected with hepatitis B virus (e.g. HBsAg positive) or HIV.
6. Has a history of malignancy ≤5 years prior to signing informed consent except for
adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer; or
has evidence of hepatocellular carcinoma (HCC) or is under evaluation for other active or
suspected malignancy.
7. Is taking or plans to take any of the prohibited medications listed in Section 5 of this
protocol within 2 weeks of Day 1.
8. Is currently participating or has participated in a study with an investigational compound
within 30 days of signing informed consent and is not willing to refrain from
participating in another such study during the course of this study.
9. has a clinical diagnosis of substance abuse of the following specified drugs within
specified timeframes:
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 alcohol, intravenous drugs, inhalational (not including marijuana), psychotropics,
narcotics, cocaine use, prescription or over-the-counter drugs: within 1 year of the
screening visit or, if shorter is judged by the investigator to be capable of complying
with study procedures, OR
NOTE: Subjects receiving opiate agonist substitution therapy are not excluded from
the study if, in the opinion of the investigator, the subject is capable of complying
with all study procedures
 history of marijuana use is deemed excessive by a physician investigator or is
interfering with the subject's daily function.  If subject's marijuana use is not deemed
excessive and does not interfere with daily function, subject must be instructed to
discontinue any current use of recreational marijuana prior to entry into trial and
throughout the trial period.
10. Female subject who is pregnant or breast-feeding, or expecting to conceive or donate
eggs from Day 1 through 14 days after the last dose of study drugs, or longer if dictated
by local regulations or male subject who is expecting to donate sperm from Day 1
through 14 days after the last dose of study drugs, or longer if dictated by local
regulations.
11. Has any of the following conditions:
 Organ transplants (including hematopoietic stem cell transplants) other than kidney,
cornea and hair.
 Poor venous access in non-dialysis patients that precludes routine peripheral blood
sampling required for this trial.
 Subject with a history of gastric surgery (e.g., stapling, bypass) or subject with a
history of malabsorption disorders (e.g., celiac sprue disease).
 Any medical condition requiring, or likely to require, chronic systemic
administration of corticosteroids during the course of the trial.
 Has uncontrolled or poorly controlled hypertension including but not limited to
hypertensive emergency or hospitalization for hypertension in preceding 3 months.
 Diagnosed with a significant cardiovascular disorder (e.g. MI or unstable angina) or
has had a cardiovascular procedure (e.g. CABG or PTCA) within 3 months prior to
signing informed consent.
 Has new or worsening signs or symptoms of congestive heart failure within 3 months
of signing informed consent.
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 Has severe active peripheral vascular disease, (e.g., manifested by claudication with
minimal activity, a non-healing ischemic ulcer, or disease which is likely to require
intervention such as with bypass or angioplasty).
 Has a recent (within 3 months prior to signing informed consent) diagnosis, episode
or recurrence of stroke, TIA or neurological disorder, including but not limited to
seizures, blackouts, or a recent (within 3 months prior to signing informed consent)
change in the dose or class of medications used to treat these conditions.
12. Subject has any condition, prestudy laboratory abnormality or ECG abnormality, or
history of any illness, which, in the opinion of the investigator, might confound the
results of the study or pose additional risk in administering the study drugs to the subject.
13. Had a life-threatening SAE during the screening period.
14. Has evidence or history of chronic hepatitis not caused by HCV, including but not limited
to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune
hepatitis.
NOTE: Subjects with history of acute non-HCV-related hepatitis, which resolved > 6
months before study entry, can be enrolled.
15. For subjects diagnosed with diabetes mellitus, chart documented HbA1c >8.5 % to
exclude uncontrolled diabetics
16. Has exclusionary laboratory values as listed below (Table 4):
Note: If any of the laboratory exclusion criteria below are met, the site may have the 
abnormal value retested one time. 
Table 4 Laboratory Exclusionary Values
Laboratory Assessment Exclusionary Value
eGFR >29 mL/min
hemoglobin < 9.0 g/dL 
neutrophils <1.5 x 103/μL (<1.2 x 103/μL for Blacks)
platelets <70 x 103/μL 
direct bilirubin >1.5 x ULN
Total Bilirubin >1.6 mg/dL unless history of Gilbert's disease. (If Gilbert’s disease is the proposed 
etiology, this must be documented in the subject’s chart)
Serum Albumin < 3.0 g/dL (lower limit of normal) of laboratory reference range
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17. Is or has an immediate family member (spouse or children) who is investigational site
or sponsor staff directly involved with this trial.
Trial Treatment(s)5.2
The treatment(s) to be used in this trial are outlined below in Table 5.









MK-5172 N/A 100 mg QD Oral 12 Weeks experimental
MK-8742 N/A 50 mg QD Oral 12 Weeks experimental
MK-5172 Placebo N/A 0 QD Oral 12 Weeks experimental
MK-8742 Placebo N/A 0 QD Oral 12 Weeks experimental
The first dose of trial treatment will be taken by the subject in the evening of Day 1 (Visit 2)
for all subjects (Immediate Treatment, Deferred Treatment and Intensive PK arms) and in the 
evening of the Week 16 visit (Visit 10) only for subjects in the deferr ed treatment arm.
Subsequent dosing will be taken in the evenings by the subject at approximately the same 
time each day (except for Week 12 and Week 28 doses which must be withheld the night 
before for the predose PK collection at those visits).
The single entity tablet formulations will be used in the Intensive PK arm and for the first 12 
weeks of dosing in the Immediate Treatment and Deferred Treatment arms.  The fixed dose 
combination formulation will be used for Week 16 to Week 28 dosing in the Deferre d 
Treatment arm.
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of trial 
treatments in accordance with the protocol and any applicable laws and regulations.
5.2.1 Dose Selection/Modification
5.2.1.1 Dose Selection (Preparation)
The rationale for selection of doses to be used in this trial is provided in Section 4.0 –
Background & Rationale.  There are no specific calculations or evaluations required to be 
performed in order to administer the proper dose to each subject.
5.2.1.2 Dose Modification (Escalation/Titration/Other)
Dose modification of MK-5172 and MK-8742 is not permitted.
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5.2.2 Timing of Dose Administration
Subjects will be instructed to take MK-5172 and MK-8742 together at bedtime. Phosphate 
binders should be taken at least 3 hours before or at least 3 hours after taking the 
investigational study medications.
If a subject misses a dose of MK-5172 and/or MK-8742 and it is less than 8 hours before the 
next dose, the missed dose should be skipped and the normal dosing schedule resumed.  
Subjects should not double the next dose in order to compensate for what has been missed. 
For the Week 12 and 28 (for deferred treatment arm) visits, all subjects will withhold their 
last evening dose of study medications.  Subjects will have a predose sample taken the next 
morning at their study visit, subjects will then take their study medications, and have a 2 hour 
post dose sample taken.
5.2.3 Trial Blinding/Masking
A double-blind/masking technique will be used.  MK-5172 and MK-8742 and placebo will 
be packaged identically so that blind/masking is maintained. The subject, the investigator and 
Sponsor personnel or delegate(s) who are involved in the [treatment] or clinical evaluation of 
the subjects are unaware of the group assignments.
The subject, the investigator and the Sponsor will not know the treatment  they are 
administered or the HCV RNA results through Week 12 of the study, including in-house  
team responsible for medical monitoring.  A separate, in-house unblinded team will have 
access to the treatment group assignments and HCV RNA results. (Please note, the 10 
subjects assigned to the intensive PK Arm will be open-label)
Pharmacokinetic (PK) measurements will be conducted in support of PK evaluations. 
Additionally, a small team as specified in a separate Modeling and Simulation (M&S) 
Modeling Analysis Plan, and who are separate from the study team, will be unblinded for the 
purpose of preparing the pharmacokinetic analyses. No PK data or results from the PK 
analyses will be shared with the study team, and the unblinded group will not be members of 
the study team.
Unblinding Procedures
A subject will not be unblinded until the Follow-Up Week 4 visit.  All safety data through the 
first 12 weeks of treatment for that subject will be cleaned prior to unblinding, changes to the 
causality asessments that occurred through Week 12 will not be allowed after the subject is 
unblinded at Follow-Up Week 4.
See Section 7.1.5.2, Blinding/Unblinding, for a description of the method of unblinding a 
subject during the trial, should such an action be warranted.
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Randomization or Treatment Allocation5.3
Treatment Allocation will occur centrally using an interactive voice response system (IVRS).   
In order to ensure enrollment of at least 20% CKD 4-5 NDD subjects, the site will identify if 
the subject is HD or NDD at the time of screening.  In addition the subject’s prior HCV
treatment status will be entered into the IVRS system at screening.
Stratification5.4
Randomization will be stratified according to the following factors:
 Dialysis:  Yes/No
 Diabetes: Yes/No
Concomitant Medications/Vaccinations (Allowed & Prohibited)5.5
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the dosing period.  If there is a clinical indication for any medication or vaccination 
specifically prohibited during dosing period, discontinuation from trial therapy or vaccination 
may be required.  The investigator should discuss any questions regarding this with the 
Sponsor Clinical Director.  The final decision on any supportive therapy or vaccination rests 
with the investigator and/or the subject's primary physician.  However, the decision to 
continue the subject on trial therapy or vaccination schedule requires the mutual agreement 
of the investigator, the Sponsor and the subject.
It is important for investigators to review each medication (prescription and non-prescription) 
the subject is taking before starting the study and at each study visit. 
 At each visit, subjects should be questioned about any new drug they are taking.
 To minimize the risk of adverse drug interactions, every effort should be m ade to
limit the number of concomitant drugs to those that are truly essential.
 Drugs known to be hepatotoxic (i.e., drugs with a warning of hepatotoxicity in the
package insert) should be avoided during the dosing period. Investigators are
encouraged to review each medication for potential hepatotoxicity by searching the
www.livertox.nih.gov website.
The following medications/therapies are contraindicated during the dosing period:
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Herbal supplements
Strong CYP3A/P-gp inhibitors, including but not limited to:
 Antibiotics: clarithromycin, erythromycin, telithromycin
 Antifungals: itraconazole, ketoconazole, voriconazole
 Antihypertensives: nifedipine
 Nefazodone
Strong and moderate CYP3A/P-gp inducers, including but not limited to: 
 Anti-infectives: nafcillin, rifampin
 Anticonvulsants: carbamazepine, phenytoin, phenobarbital
 bosentan
 modafinil
 St. John's Wort
OATP inhibitors, including but not limited to:
 Immunosuppressants: cyclosporine
 Anti-infectives: rifampin
 Lipid lowering agents: gemfibrozil
 eltrombopag
 lapatinib
HIV medications, including but not limited to:
 efavirenz
 etravirine
 all ritonavir-boosted and unboosted HIV protease inhibitors






 pravastatin at doses greater than 10 mg
 Note: Questions regarding use of other statins should be directed to the Sponsor.
In general, CYP3A4 substrates with narrow therapeutic ranges (e.g. alfentanil, astemizole, 
cisapride, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, terfenadine) are not 
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prohibited, but their levels have the potential to be increased by approximately 30%.  
Therefore, subjects taking these medications should be monitored closely or dose adjusted 
appropriately.
Investigational agents are not permitted.
Systemic corticosteroids (dose equivalent to ≥ 10 mg prednisone per day, except in the case 
of rapid steroid tapers <1 week in duration) are not permitted.
Concomitant medications and therapies discontinued during the dosing period may be 
restarted 2 weeks after the last dose of study drug is administered and may be continued
during the follow-up period.
Allowed Medications
The following concomitant medications are allowed in this study:
Phosphate binders such as
• calcium carbonate/calcium acetate
• sevelamer
• lanthanum
Note: Subjects taking phosphate binders must do so either at least 3 hours before or
at least 3 hours after taking the investigational study medications.
Statins such as
• pravastatin: use the lowest possible effective dose, but do not exceed a daily dose of
10 mg
Note: Questions regarding use of other statins should be directed to the Sponsor.
Medications for anemia such as
• Erythropoetin
Antihypertensives
• ACE inhibitors/ARBs: enalapril, captopril, lisinopril, ramipril, valsartan, losartan,
telmisartan
• Most beta blockers: atenolol, metoprolol, propranolol
Note: for other beta blockers, please consult with the Sponsor
• calcium-channel blockers: verapamil, diltiazem, amlodipine
Note: For other antihypertensives, please consult with the Sponsor
• hydralazine, clonidine, minoxidil, isosorbide nitrates
Medications for hyperparathyroidism
• ergocalciferol
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Note: For other medications not listed here, please consult with the Sponsor.
Rescue Medications & Supportive Care5.6
No rescue or supportive medications are specified to be used in this trial.
Diet/Activity/Other Considerations5.7
Dietary Considerations
MK-5172 and MK-8742 can be taken without regard to food; however, intake of grapefruit 
or grapefruit juice is prohibited during the dosing period of the trial.  
Subjects taking phosphate binders must do so either 3 hours before or three hours after the 
investigational study medications administered in this study.
Considerations for Study Visits
Procedures visits should be scheduled as close to the indicated study days and study weeks as 
possible. See the Study Flow Chart in Section 6 for a complete listing of study procedures 
required at each visit. Collection of PK samples (predose and/or postdose) must be taken as 
indicated in Table 7, Table 8, and Table 9 in Section 7.1.4.2
Subject Withdrawal/Discontinuation Criteria5.8
Subjects may withdraw consent at any time for any reason or be dropped from the trial at the 
discretion of the investigator should any untoward effect occur.  In addition, a subject may be 
withdrawn by the investigator or the Sponsor if enrollment into the trial is inappropriate, the 
trial plan is violated, or for administrative and/or other safety reasons.  Specific d etails 
regarding discontinuation or withdrawal procedures; including specific details regarding 
withdrawal from Future Biomedical Research, are provided in Section 7.1.4 – Other 
Procedures.
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In this trial, a subject may discontinue from treatment but continue to participate in the 
regularly scheduled activities, as long as the subject does not withdraw consent.  
Discontinuation from treatment is permanent.  Once a subject has discontinued treatment, 
even though he/she continues to be monitored in the trial, he/she shall not be allowed to 
begin treatment again.
A subject must be discontinued from the trial for any of the following reasons:
● The subject or legal representative (such as a parent or legal guardian) withdraws
consent.
 The subject has a medical condition or personal circumstance which, in the opinion of
the investigator and/or Sponsor, places the subject at unnecessary risk through
continued participation in the trial or does not allow the subject to adhere to the
requirements of the protocol.
A subject must be discontinued from treatment (but may continue to be monitored in the 
trial) for any of the following reasons:
 Subject meets any virologic failure criteria (see Section 4.2.3.1.1.2)
 Subject becomes pregnant during the trial.
 A physician investigator feels it is in best interest of the subject to discontinue.
 Subject receives a renal transplant.
 The subject’s ALT or AST increases to >500 IU/L.
 The subject’s ALT or AST increases to >3x baseline, is >100 IU/L, and there is a
simultaneous increase in total bilirubin >2x ULN and/or INR >1.5.
 The subject’s ALT or AST increases to >3x the nadir value, is >100 IU/L, and there
is a simultaneous increase in total bilirubin > 2x ULN and/or INR >1.5.
 The subject’s ALT or AST increases to >3x baseline, is >100 IU/L, and is temporally
associated with the new onset or worsening of any of the following adverse events
that are of moderate or severe intensity and deemed by the investigator to be at least
possibly related to MK-5172 and or MK-8742:  nausea, vomiting, right upper
quadrant pain or tenderness, and/or eosinophilia (>5%).
 The subject’s ALT or AST increases to >3x the nadir value, is >100 IU/L, and is
temporally associated with the new onset or worsening of any of the following
adverse events that are of moderate or severe intensity and deemed by the investigator
to be at least possibly related to MK-5172 and or MK-8742:  nausea, vomiting, right
upper quadrant pain or tenderness, and/or eosinophilia (>5%).
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 The subject’s alkaline phosphatase increases to >3x ULN, there is a simultaneous
increase in total bilirubin > 2x ULN and other causes of elevated alkaline phosphatase
are excluded.
 The subject’s alkaline phosphatase increases to >5x ULN and other causes of elevated
alkaline phosphatase are excluded.
A subject may be discontinued from treatment for any of the following reasons:
 SAE assessed by the physician investigator as possibly or probably related to study
medication. Investigator may continue the subject in the trial, if it is deemed to be in
the best interest of the subject to stay on the study treatment.
 Failure to comply with the dosing, evaluations, or other requirements of the trial
Subject Replacement Strategy5.9
A subject who discontinues from the trial will not be replaced.
Beginning and End of the Trial5.10
The overall trial begins when the first subject signs the informed consent form.  The overall 
trial ends when the last subject completes the last trial visit, discontinues from the trial or is 
lost to follow-up (i.e. the subject is unable to be contacted by the investigator).
Clinical Criteria for Early Trial Termination5.11
Early trial termination will be the result of the criteria specified below:
Early Trial Termination Due to Safety
If >10 of 115 in the immediate treatment arm or Intensive PK arm meet any of the safety 
criteria listed below, then the study should be terminated.
 ALT or AST increases to >500 IU/L.
 ALT or AST increases to >3x baseline, is >100 IU/L, and there is a simultaneous
increase in total bilirubin >2x ULN and/or INR >1.5.
 ALT or AST increases to >3x the nadir value, is >100 IU/L, and there is a
simultaneous increase in total bilirubin > 2x ULN and/or INR >1.5.
 ALT or AST increases to >3x baseline, is >100 IU/L, and is temporally associated
with the new onset or worsening of any of the following adverse events that are of
moderate or severe intensity and deemed by the investigator to be at least possibly
related to MK-5172: nausea, vomiting, right upper quadrant pain or tenderness,
and/or eosinophilia (>5%).
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 ALT or AST increases to >3x the nadir value, is >100 IU/L, and is temporally
associated with the new onset or worsening of any of the following adverse events
that are of moderate or severe intensity and deemed by the investigator to be at least
possibly related to MK-5172: nausea, vomiting, right upper quadrant pain or
tenderness, and/or eosinophilia (>5%).
 alkaline phosphatase increases to >3x ULN, a simultaneous increase in total bilirubin
> 2x ULN and other causes of elevated alkaline phosphatase are excluded.
 alkaline phosphatase increases to >5x ULN and other causes of elevated alkaline
phosphatase are excluded.
Early Trial Termination Due to Virologic Failure Criteria (rebound, non-response, 
breakthrough, relapse):
All Early Trial Termination decisions will be based on the per-protocol population.
If >7 of the first 20 patients in the immediate treatment group meet virologic failure criteria, 
no additional subjects will be enrolled and the study will be terminated.
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6.0 TRIAL FLOW CHART








 7 2 3 4 6 8 10 12
NA NA NA NA NA NA NA NA NA
FU4 FU 12 FU 24
Unsched/HCV 






Deferred Treatment Arm 16 17 18 19 20 22 24 26 28
















weeks ±4 weeks NA
ADMINISTRATIVE PROCEDURES
Informed Consent x




Subject Identification Card x
Medical History x




Review Study Medication 
Diary
x x x x x x x x x
x
x x x x x x x x x x




Physical Examination1 x x x x x x x x
Weight x x x x x x
Height x
12-Lead ECG x x x x x x x x
Vital Signs x x x x x x x x x x x x x x x x x x x x x x
Subject confirmation of birth 
control
x x x x x x x x x x
x
x x x x x x x x
x16
x x
Review (Serious) Adverse 
Events2
x x x x x x x x x x
x
x x x x x x x x
x
x x x x
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NA NA NA NA NA NA NA NA NA
FU4 FU 12 FU 24
Unsched/HCV 






Deferred Treatment Arm 16 17 18 19 20 22 24 26 28
















weeks ±4 weeks NA
LABORATORY SAFETY EVALUATIONS13
Coagulation x x x x x x x x x x x x x x x x x x x x x x x x
Chemistry & Hematology x x x x x x x x x x x x x x x x x x x x x x x x
Urinalysis 3 x x x x x x x x x x x x x x x x x x x x x x
Cryoglobulinemia labs15 x x x x
HBA1C (only for subjects with 
a prior diagnosis of diabetes)
x x x x x x
HBsAg x
HIV screen x
Pregnancy Test (females of 
child bearing potential only)4
x x x x x x x x
PATIENT REPORTED OUTCOME
SF36® Health Survey x x x X x
PHARMACOKINETICS
MK-5172 (population PK in 
all subjects)
X X X x x
MK-8742 (population PK in 
all subjects)
X X X x x
MK-5172 (intensive PK Arm 
only)
X X X x x
MK-8742 (intensive PK Arm 
only)
X X X x x









HCV Genotype Determination x x
HCV RNA Level7 x x x x x x x x x x x x x x x x x x x x x x x X11




x x x X11
Blood (DNA) for genetic 
analysis6
x
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NA NA NA NA NA NA NA NA NA
FU4 FU 12 FU 24
Unsched/HCV 






Deferred Treatment Arm 16 17 18 19 20 22 24 26 28
















weeks ±4 weeks NA
DRUG ADMINISTRATION
MK-5172 or placebo 
(blinded)8
x x x x x x x x x11,12
MK-8742 or placebo(blinded)8 x x x x x x x x x11,12
MK-5172 (open label)8 x11,12 x x x x x x x x X11,12
MK-8742 (open label)8 x11,12 x x x x x x x x x11,12
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NOTE: Subjects in the Immediate treatment arm will have Visits 1-10, be unblinded at Week 16, and will then move to Visits 20-22.  Subjects in the Deferred treatment arm will have Visits 1-
10, be unblinded at Week 16, and will then have visits 11-22. 
*Subjects in the Intensive PK arm will have Visits 1-10 and will then move to Visits 20-22.
1 A comprehensive PE will be done at screening and baseline (Day1). For all other visits a focused PE will be conducted when clinically indicated.
2 Review of Adverse Events should include collecting serious adverse events throughout the study and collecting all adverse events Day 1 (post-dose) through 14 days following the last dose of 
study drug.  Adverse events occurring prior to study drug administration or after study drug discontinuation, as a result of a protocol-specified procedure or intervention, should also be 
reported.
3 Urinalysis will be obtained on all NDD subjects and when feasible on HD subjects.  
4 Female subject who is of childbearing potential.  Serum pregnancy tests at screening visit.  Routinely use urine pregnancy tests beginning predose on Day 1, however, a serum pregnancy test 
can be used for patients on hemodialysis who do not produce enough urine for testing..  The urine pregnancy test results must be provided to the investigator and/or site personnel.  Subjects 
should be instructed to contact the investigator and/or site personnel immediately if the result of the self-pregnancy test is positive.
5 Blood samples will be collected for HCV viral resistance testing at baseline, viral failure confirmation visit, and FU visits.  At the same time points, samples will be collected for proteomics, and 
metabolomics and other exploratory analysis.  
6 Blood sample will be collected for IL28B genotyping and genetic analysis for ADME and HLA genes.  The sample should be sent as a single whole blood sample and the testing facility will extract 
DNA and split into 2 aliquots for each analysis.   
7 Informed Consent for future biomedical research samples must be obtained before the DNA samples are collected.  DNA for analysis should be obtained predose, on Day 1 (or with the next 
scheduled blood draw), as the last sample drawn, on randomized subjects only, or at a later date as soon as the informed consent is obtained. Any leftover plasma from HCV RNA or leftover 
plasma for HCV viral resistance and biomarker will be stored for future research if the subject consents to participate in the FBR sub-study.  
8 MK-5172 and MK-8742 will be provided on a monthly basis.  The site will call the Interactive Voice Response System (IVRS) to obtain component ID assignment.  
9 Procedures on Day 1 should be performed prior to the first evening dose unless specified otherwise.
10 If a subject is confirmed viral failure during therapy (i.e. break through), then the sample collection for HCV RNA and Viral Resistance/Biomarker is not needed for the early discontinuation visit.
11 There will be no dispensing of study medication on this day.  However, the subject will take their last dose(s) of week 12 on that day.
12 For the Week 12 (Week 28 for deferred treatment arm), all subjects will hold their last evening dose of study medications.  Subjects will have predose sample taken the next morning at their 
study visit.
13 All laboratory sampling should be performed prior to dialysis on days with a scheduled dialysis session.
14 Unblinding will occur at Week 16 of the study after all data through Week 12 and safety follow-up after Week 12 have been completed, data cleaned and queries resolved.  If the subject is 
determined to have received active therapy during the first 12 weeks, the visit at Week16 will be the FU 4 visit and those study procedures should be followed.  If the subject was determined 
to have received placebo during the first 12 weeks, the visit at Week 16 will be counted as Visit 11 (Day 1 of active dosing) and those study visits followed.   Unblinding is not applicable to the 
Intensive PK Arm.
15 Serum cryocrit, C4 complement component, and Rheumatoid factor should be collected for all subjects with cryoglobulinemia reported in their Medical History.  Because of stability and 
shipping issues, these samples should only be collected on a Monday or Tuesday.
16 Confirmation of birth control is only needed for 14 days past last dose of study drugs.
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7.0 TRIAL PROCEDURES
Trial Procedures7.1
The Trial Flow Chart - Section 6.0 summarizes the trial procedures to be performed at each 
visit.  Individual trial procedures are described in detail below.  It may be necessary to 
perform these procedures at unscheduled time points if deemed clinically necessary by the 
investigator.
Furthermore, additional evaluations/testing may be deemed necessary by the investigator and 
or the Sponsor for reasons related to subject safety. In some cases, such evaluation/testing 
may be potentially sensitive in nature (e.g., HIV, Hepatitis C, etc.), and thus local regulations 
may require that additional informed consent be obtained from the subject.  In these cases, 
such evaluations/testing will be performed in accordance with those regulations.
7.1.1 Administrative Procedures
7.1.1.1 Informed Consent
The investigator or qualified designee must obtain documented consent from each potential 
subject or each subject’s legally acceptable representative prior to participating in a clinical 
trial or Future Biomedical Research.
7.1.1.1.1 General Informed Consent
Consent must be documented by the subject’s dated signature or by the subject’s legally 
acceptable representative’s dated signature on a consent form along with the dated signature 
of the person conducting the consent discussion. 
A copy of the signed and dated consent form should be given to the subject before 
participation in the trial.
The initial informed consent form, any subsequent revised written informed consent form 
and any written information provided to the subject must receive the IRB/ERC’s 
approval/favorable opinion in advance of use.  The subject or his/her legally acceptable 
representative should be informed in a timely manner if new information becomes available 
that may be relevant to the subject’s willingness to continue participation in th e trial.  The 
communication of this information will be provided and documented via a revised consent 
form or addendum to the original consent form that captures the subject’s dated signature or 
by the subject’s legally acceptable representative’s dated signature.
Specifics about a trial and the trial population will be added to the consent form template at 
the protocol level.  
The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations 
and Sponsor requirements.
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7.1.1.1.2 Consent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research consent 
to the subject, answer all of his/her questions, and obtain written informed consent before 
performing any procedure related to the Future Biomedical Research sub-trial.  A copy of the 
informed consent will be given to the subject.
7.1.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee 
to ensure that the subject qualifies for the trial.
7.1.1.3 Subject Identification Card
All subjects will be given a Subject Identification Card identifying them as participants in a 
research trial.  The card will contain trial site contact information (including direct telephone 
numbers) to be utilized in the event of an emergency.  The investigator or qualified designee 
will provide the subject with a Subject Identification Card immediately after the subject 
provides written informed consent.
7.1.1.4 Medical History
A medical history will be obtained by the investigator or qualified designee.  
7.1.1.5 Prior and Concomitant Medications Review
7.1.1.5.1 Prior Medications
The investigator or qualified designee will review prior medication use, including any 
protocol-specified washout requirement, and record prior medication taken by the subject 
within 30 days before starting the trial.
7.1.1.5.2 Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the subject 
during the trial.
7.1.1.6 Assignment of Screening Number
All consented subjects will be given a unique screening number that will be used to identify 
the subject for all procedures that occur prior to randomization or allocation.  Each subject 
will be assigned only one screening number.  Screening numbers must not be re-used for 
different subjects.  
Any subject who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
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7.1.1.7 Assignment of Randomization Number
All eligible subjects will be randomly allocated and will receive a randomization number.  
The randomization number identifies the subject for all procedures occurring after 
randomization.  Once a randomization number is assigned to a subject, it can never be re-
assigned to another subject.
A single subject cannot be assigned more than 1 randomization number.
7.1.1.8 Trial Compliance (Medication/Diet/Activity/Other)
The investigator/study coordinator will give the subject a Study Medication Diary to be 
completed during the study period.  The investigator/study coordinator will be responsible 
for entering the subject’s identification (allocation number), visit number, and the dates 
before giving the diary card to the subject.  The subject will be instructed to record 
dates/times and the number of tablets or capsules of study drug doses on the diary card for 
the entire time period.  Only the subject should enter information on the diary card.  The 
subject is to return the completed diary card at each scheduled visit.  At visits when 
used/unused study medications are returned, site personnel must verify the accuracy of the 
dosing diary by comparing entries with amounts of returned study medication.  If a 
discrepancy is noted, investigator/study coordinator must discuss the discrepancy with the 
subject, and the explanation must be documented.  Only the subject shall make any changes 
to the entries on the diary card.  The subject will initial the diary card to confirm that the 
information is accurate.  The investigator/study coordinator will be responsible for 
transferring the appropriate information from the diary card onto the appropriate case report 
form.
Interruptions from the protocol specified treatment plan require consultation between the 




All physical examinations must be performed by the principal investigator or sub-
investigator (physician, physician assistant or nurse practitioner).
A complete physical examination, performed at the Screening visit and Day 1 includes the 
following assessments: general appearance, head, eyes, ears/nose/ throat, neck, lymph nodes, 
skin, lungs, heart, abdomen, musculoskeletal, and neurologic evaluations. Breast, rectal, and 
genitourinary/pelvic exams should be performed when clinically indicated. For all other 
visits, a focused exam will be performed when clinically indicated. Any significant changes 
between the screening visit and Day 1 should be noted in the Medical History eCRF. Any 
significant changes after receiving study therapy at Day 1 must be reported as adverse events 
and entered on the adverse event eCRF.  If the subject is discontinued for any reason during 
the treatment phase, every attempt should be made to perform a final physical examination.  
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Patients with a diagnosis of cryoglobulinemia at study entry should be specifically evaluated 
for signs and symptoms of the disease.
7.1.2.2 Weight and Height Assessment
The subject's weight should be assessed as mentioned in the flow chart. Clinically significant 
changes from Day 1 should also be captured as AEs in the CRF.  Weight and height will also 
be utilized to assess the patients GFR in order to monitor the renal disease status.
7.1.2.3 12-Lead ECG
Special care must be taken for proper lead placement.  Subjects should be shaved as 
necessary for proper lead placement.  Subjects should be resting in a semi-recumbent 
position for at least 10 minutes prior to having ECG readings obtained. However, clinically 
significant findings from the screening ECG must be captured in the medical history eCRF. 
For ECGs performed during treatment or during the follow-up period, any clinically 
significant changes compared with the screening ECG must be captured as AEs.
7.1.2.4 Vital Signs
Vital signs will include heart rate (sitting), blood pressure (sitting), and oral temperature.  
Subjects should be resting in a semi-recumbent position for at least 10 minutes prior to 
having vital sign measurements obtained.
Note:  Oral temperatures should be taken, but if oral is not possible, tympanic, rectal, and 
axillary temps may be taken,
After the screening visit, the site should indicate whether or not the result is clinically 
significant and if any subsequent changes constitute an adverse event.
7.1.2.5 Birth Control Confirmation
Confirmation must be obtained by site personnel that subjects and their partner(s) are using 
acceptable methods of contraception. This assessment must be documented in the subject's 
study chart at each specified visit.
7.1.2.6 Adverse Events
The principal investigator or sub-investigator (physician, physician assistant or nurse 
practitioner) must determine the severity and relationship to study medication(s) of all 
adverse events.  A physician investigator must review, initial and date the severity of all 
adverse events and their relationship to study medications when initial assessment of an 
adverse event is made by a physician assistant or nurse practitioner. Designated medical 
practitioners must be licensed and the responsibilities transferred to them must be 
documented in the site file. For details please refer to Section 7.2
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7.1.2.7 Noninvasive Methods of Cirrhosis Evaluation 
FibroScan - This method for assessing liver cirrhosis has gained increasing acceptance. In the 
US, this methodology is FDA approved and in other countries it is often the preferred method 
of assessment.  Fibroscan results are influenced by a number of confounders including ALT, 
ascites, and underlying disease.  Hepatitis C is one of the best studied and is the disease state 
with the most reproducible/reliable results.  Fibroscan has been evaluated in many liver 
diseases for the staging of liver fibrosis, and has been demonstrated to be very effective  or 
differentiating cirrhosis (F4) from no cirrhosis (<F4), but it is less capable of  differentiating 
gradations of fibrosis.  In a large study by Castera, et al [42], a population of patients with 
chronic hepatitis C, a cut-off of 12.5 kPa was selected for cirrhotics. At this cut-off, the 
sensitivity and specificity of the test for cirrhosis were 87% and 91%, respectively and the 
negative predictive value was 95%. Since this analysis was assessed specifically in patients 
with chronic hepatitis C, the cut-off value ≤ 12.5 kPa used by Castera was selected to exclude 
cirrhotics in the current study.
FibroTest + APRI – Various methodologies have been developed in order to improve the  
sensitivity and specificity of blood tests used to diagnose cirrhosis in patients with chronic 
hepatitis C infections.  One such algorithm, the Sequential Algorithm for Fibrosis Evaluation 
(SAFE), which uses a combination of Fibrotest and the aspartate aminotransferase-to platelet 
ratio index (APRI) is very accurate for diagnosing cirrhosis [43]. For cirrhosis, the SAFE for 
F4 algorithm provides a diagnostic accuracy of 89.5% with a negative predictive value of 
94.6%. Using this algorithm, it is estimated that only 6.2% of the patients would need a liver 
biopsy to confirm the diagnosis of cirrhosis. The cut-off values for excluding cirrhotics using 
the two tests, without the use of liver biopsy, are ≤1 and ≤0.48 for FibroTest and APRI when 
the SAFE for F4 is used.  This study uses this method with one variation and that is the more 
stringent requirement that both the APRI and FibroTest need to be consistent with no 
cirrhosis, i.e. APRI is ≤1 AND Fibrotest ≤0.48.  Accordingly, the Sponsor is confident these 
cut-off values that will differentiate cirrhotic from non-cirrhotic patients with reasonable 
accuracy in this study. 
7.1.3 Patient-Reported Outcomes 
SF36v2® Health Survey
Health-related quality of life will be assessed using the SF-36v2® Health Survey, Acute (1-
week recall) Form, a generic health survey, which includes 36 questions to measure 
functional health and well-being from the patient’s perspective. The SF-36v2® measures 
each of the following eight health domains: Physical Functioning, Role Limitations-Physical, 
Bodily Pain, General Health, Vitality, Social Functioning, Role Limitations-Emotional, and 
Mental Health. The eight health domain scores contribute to the computation of the Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores.
Subjects will be administered the SF-36v2® on an electronic device and are to complete the 
SF-36v2® on their own at the beginning of the appropriate study visit [Day 1, Week 12, 
Week 28 (deferred treatment arm only), Follow-Up Week 12, and Early Discontinuation].  
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Every attempt should be made to complete the questionnaires prior to receiving study 
treatment, discussing any medical conditions, or receiving any medical results (see study 
flow chart). It should take subjects approximately 5-10 minutes to complete the SF-36v2®.
7.1.4 Laboratory Procedures/Assessments
Details regarding specific laboratory procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre-trial to post-trial visits), including approximate blood/tissue volumes 
drawn/collected by visit and by sample type per subject can be found in Section 12.4.  
NOTE:  All laboratory sampling should be performed prior to dialysis on days with a 
scheduled dialysis session.
7.1.4.1 Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)
Laboratory tests for hematology, chemistry and urinalysis are specified in Table 6.  
NOTE: For subjects on hemodialysis, samples should be drawn prior to any scheduled 
HD.
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Table 6 Laboratory Tests
Hematology Chemistry Urinalysis Other
Hematocrit Albumin Specific Gravity Hemoglobin A1C (HbA1c)
Hemoglobin Alkaline phosphatase pH Hepatitis C Virus Genotype
Platelet count Alanine aminotransferase (ALT) Glucose Plasma HCV RNA




Protein Prothrombin time (PT)
Erythrocytes 
(RBC count)
Creatinine Ketones International normalized 
Ratio (INR)
Creatinine Clearance (for CKD 
patients throughout)
Occult Blood Human Chorionic 
gonadotropin 
(Urine pregnancy test kits to 
sites) 
Creatine Kinase Bilirubin HIV-1 serology (screening 
only)
Gamma-glutamyltransferase Nitrite HBsAg (screening only)
Glucose (serum glucose) Leukocytes APRI calculation (screening 
only)
Potassium Erythrocytes Fibrosure® (Fibrotest) as 
requested by site for entry 
critiera (may be performed 
locally)
Sodium Microscopic exam, if 




Direct Bilirubin For subjects with 




Indirect Bilirubin  Rheumatoid factor






The decision as to which plasma samples collected will be assayed for evaluation of 
pharmacokinetics/pharmacodynamics will be collaboratively determined by the Departments 
of Quantitative Pharmacology and Pharmacometrics (QPP) and the appropriate department 
within Late-Stage Development.  If indicated, these samples may also be assayed and/or 
pooled for assay in an exploratory manner for metabolites and/or additional 
pharmacodynamic markers.
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7.1.4.2.1 Blood Collection for Plasma MK-5172 and MK-8742
Sample collection, storage and shipment instructions for plasma samples will be provided in 
the operations/laboratory manual. 
All subjects allocated and enrolled in the study (all 3 treatment arms) will be part of the 
population PK group (i.e. sparse PK sampling scheme).  See Table 7 for sampling scheme.  
For the Week 12 sampling, all subjects will withhold their last evening dose of study 
medications.  Subjects will have a predose sample taken the next morning at their study visit, 
subjects will then take their study medications, and have a 2 hour post dose sample taken.  
For the Week 28 sampling, subjects in the deferred treatment arm will hold their last evening 
dose of study medications. Subjects will have a predose sample taken the next morning at 
their study visit, subjects will then take their study medications, and have a 2 hour post dose 
sample taken. 
Five (5) HD subjects and five (5) subjects not on HD will be allocated to an intensive PK 
subgroup receiving open-label MK-5172 in combination with MK-8742.  See Table 8 for 
sampling scheme. At Week 4, these 10 subjects will take their study medications in the PM 
and be domiciled overnight for the sample collections. The 24-hour PK collection in HD and 
non-HD subjects (Week 4) will be used to characterize the representative steady-state 
exposures in both populations.
An additional ten (10) HD subjects and ten (10) non-dialysis subjects will be identified from 
the immediate and deferred treatment arms to participate in an evening pre-dose PK cohort, 
but only the samples from the subjects on active treatment (immediate treatment arm) will be 
analyzed.  See Table 9 for sampling scheme. A visiting nurse will collect a pre-dose sample 
at the protocol specified Week 4 PK timepoint prior to their PM dose. The predose PK 
sample collected in the evening pre-dose PK cohort will be used to correlate the PK 
exposures between PK samples collected in the AM (e.g., Week 12, 28) and the PM (e.g., 
Week 4).
All PK samples (from population PK, intensive PK, and evening pre-dose PK) will be used 
to evaluate not only PK exposures in the non-dialysis CKD and HD populations, but also to 
assess the PK/PD and PK/AE relationships of MK-5172 and MK-8742, as appropriate.  
03XKX6
Product:  MK-5172 55
Protocol/Amendment No.: 052-04 
MK-5172-052-04 Final Protocol 04-Jun-2014










































1 ~4 mL of blood will be collected at each specified time point for plasma PK assessments of MK-5172 
and MK-8742.
2 Time Relative to last Dose of MK-5172, MK-8742 must be recorded in INFORM
3 The date and time of the last MK-5172, MK-8742 dose prior to all PK sample collection must be 
recorded in INFORM
Note: At the time of PK sample collection, subjects will be asked to provide information regarding the 
time/date of the last MK-5172, MK-8742 dose prior to the PK sample collection. (This can also be 
obtained by referencing the subject's study medication diary).
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1 ~4 mL of blood will be collected at each specified time point for plasma PK assessments of MK-5172 
and MK-8742.
2 Time Relative to last Dose of MK-5172, MK-8742 must be recorded in INFORM
3 The date and time of the last MK-5172, MK-8742 dose prior to each PK sample collected must be 
recorded in INFORM
4 Since all subjects will have samples taken on Day 1 and on Week 12 for population PK, additional 
samples for Intensive PK do not need to be collected.
Note: At the time of PK sample collection, subjects will be asked to provide information regarding the 
time/date of the last MK-5172, MK-8742 dose prior to the PK sample collection. (This can also be 
obtained by referencing the subject's study medication diary).
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1 ~4 mL of blood will be collected at each specified time point for plasma PK assessments of MK-5172 
and MK-8742.
2 Time Relative to last Dose of MK-5172, MK-8742 must be recorded in INFORM
3 The date and time of the last MK-5172, MK-8742 dose prior to each PK sample collected must be 
recorded in INFORM
4 Since all subjects will have samples taken on Week 12 for population PK, additional samples for evening 
pre-dose PK do not need to be collected
Note: At the time of PK sample collection, subjects will be asked to provide information regarding the 
time/date of the last MK-5172, MK-8742 dose prior to the PK sample collection. (This can also be 
obtained by referencing the subject's study medication diary).
7.1.4.3 Future Biomedical Research
The following specimens are to be obtained as part of Future Biomedical Research:
 Blood for genomics use
 Leftover plasma from HCV RNA
 Leftover plasma from viral resistance and biomarkers
7.1.4.4 HCV Evaluation
The following specimens are to be obtained as part of Efficacy/Pharmacogenetic 
Measurements:
 Samples for HCV Genotype evaluation must be obtained as part of the main consent
for inclusion in the study.
 Blood must be drawn from each subject as part of the main consent to assess HCV
RNA plasma levels at various time points as shown in the flow chart.   HCV-RNA in
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plasma will be measured using a COBAS™ AmpliPrep/COBAS™ Taqman™ HCV 
Test, v2.0 ® assay. Lleftover plasma may be used for future biomedical research 
only if the subject signed for future biomedical consent.
 Blood must be drawn from each subject as part of the main consent to assess viral
resistance mutation and processed as instructed by the central laboratory manual.
 Protein and metabolites may be measured from blood samples to compare biomarkers
measured prior to treatment, to biomarkers measured at several time points during
treatment that correlate with subject response to treatment (sustained viral response).
 Samples collected for IL28B genotyping and genetic analysis for ADME and HLA
genes associated with liver injury are obtained at Day 1 as part of the main consent.
The assay performed is specific to the IL28B gene region and genes related to HLA
and ADME.  Any remaining specimen after the genetic analysis has been performed
will be destroyed.
Note: Samples may also be used for future assay development and validation
7.1.5 Other Procedures
7.1.5.1 Withdrawal/Discontinuation
Subjects who discontinue/withdraw from treatment prior to completion of the treatment
regimen should be encouraged to continue to be followed for all remaining study visits.
7.1.5.1.1 Withdrawal From Future Biomedical Research
Subjects may withdraw their consent for Future Biomedical Research and have their 
specimens and all derivatives destroyed.   Subjects may withdraw consent at any time by 
contacting the principal investigator for the main trial.  If medical records for the main trial 
are still available, the investigator will contact the Sponsor using the designated mailbox 
(clinical.specimen.management@merck.com), and a form will be provided by the Sponsor to 
obtain appropriate information to complete specimen withdrawal.  Subsequently, the 
subject's specimens will be removed from the biorepository and be destroyed.  A letter will 
be sent from the Sponsor to the investigator confirming the destruction. It is the 
responsibility of the investigator to inform the subject of completion of destruction.  Any 
analyses in progress at the time of request for destruction or already performed prior to the 
request being received by the Sponsor will continue to be used as part of the overall research 
trial data and results.   No new analyses would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (e.g., if the 
investigator is no longer required by regulatory authorities to retain the main trial records) or 
the specimens have been completely anonymized, there will no longer be a link between the 
subject’s personal information and their specimens.  In this situation, the request for 
specimen destruction cannot be processed.
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7.1.5.2 Blinding/Unblinding
IVRS/IWRS should be used for emergency unblinding in the event that this is required for 
subject safety.  The emergency unblinding call center will provide after-hours emergency 
unblinding coverage when the investigator is not available. 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., date 
and reason) must be documented promptly, and the Sponsor Clinical Director notified as 
soon as possible.  Only the principal investigator or delegate and the respective subject’s 
code should be unblinded.  Trial site personnel and Sponsor personnel directly associated 
with the conduct of the trial should not be unblinded.
7.1.5.3 Calibration of Critical Equipment
The investigator or qualified designee has the responsibility to ensure that any critical device
or instrument used for a clinical evaluation/test during a clinical trial that provides important 
information about inclusion/exclusion criteria and/or safety or efficacy parameters shall be 
suitably calibrated and maintained to ensure that the data obtained is reliable and/or 
reproducible.  Documentation of equipment calibration must be retained with the study 
documentation as source documentation at the trial site.
Critical Equipment for this trial includes:
None
7.1.5.4 Rescreening
 Subjects who have previously completed the screening visit (Visit 1) and were deemed
eligible for randomization into this study, but failed to be randomized within the 60-day
window, may be rescreened to re-evaluate study eligibility.  To reconfirm the subject's
eligibility, all pre-study evaluations should be repeated, after approval from the
SPONSOR, except for the following:
 HCV GT Determination
 Liver biopsy
 12-Lead ECG
If any of the laboratory exclusion criteria are met, the site may have the abnormal value 
retested one time.
7.1.5.5 PK Sampling Time Points
Subjects must follow the protocol defined specific time points for predose or post dose in 
respect to study medication administration for PK sample collection.  If predose PK sample 
is required by the protocol, the subject should withhold their dose the day of PK sample.  For 
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detailed time points of PK sample collection please refer to Table 7, Table 8 and Table 9 in 
Section 7.1.4.2.1.
7.1.6 Visit Requirements
Visit requirements are outlined in Section 6.0 - Trial Flow Chart.   Specific procedure-related 
details are provided above in Section 7.1 - Trial Procedures.
7.1.6.1 Screening
Within 60 days prior to administration of the initial dose of study drug, potential subjects will 
be evaluated to determine that they fulfill the entry requirements as set forth in Section 5.1.  
Verification should be obtained to confirm that the subject is non-cirrhotic and the subject’s 
fibrosis score must be captured to support secondary data analysis.  The primary etiology of 
the subject’s renal disease must be captured.  The investigator will discuss with each 
potential subject the nature of the study, its requirements, and its restrictions.
Subjects will be instructed that they are required to use two acceptable methods of birth 
control from at least 2 weeks prior to Day 1 and throughout treatment, or longer if dictated by 
local regulations, after the last dose of study medication.
Subjects will be instructed about the restrictions for concomitant medications, as noted in 
Section 5.5.
All screening procedures listed for Visit 1 in the Study Flow Chart must be completed and 
subject eligibility confirmed by the investigator prior to the subject’s randomization and drug 
administration.
All subjects will be given a card, at the time of screening, identifying them as participants in 
a research study. The card will contain contact information (including direct telephone 
numbers) to be utilized in the event of an emergency.
7.1.6.2 Treatment Period Visit
Treatment Day 1 (Visit 2)
Pretreatment Procedures
Day 1 procedures listed on the Study Flow Chart should be performed prior to dosing unless 
specified otherwise. For female subjects, a urine pregnancy test will be performed at the site 
prior to study drug initiation.  If the urine pregnancy test result is negative, the subject will be 
eligible for randomization and the remainder of the pretreatment (Day 1) testing/procedures 
will be performed.  If the urine pregnancy test result is positive, the subject must not be 
randomized.
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Blood will be collected for assay of safety evaluations, plasma HCV RNA, and PK 
measurements.  These samples will be sent to the appropriate central laboratory(ies) 
following the procedure(s) set forth in the manual(s).
Additional samples will be collected for genetic evaluation of host parameters related to the 
response of HCV subjects to MK-5172 and MK-8742 therapies.
7.1.6.3 Drug Administration
Following completion of the Day 1 procedures and confirmation of eligibility, the site 
pharmacist or study coordinator will contact the IVRS for assignment of the drug to be 
administered.  Sites should not call IVRS for drug administration until the subject has met all 
criteria for the study and are ready to receive the first dose of study medication on Day 1.
The first dose of trial treatment will be taken by the subject in the evening of Day 1 (Visit 2) 
for all subjects (Immediate Treatment, Deferred Treatment and Intensive PK arms) and in the 
evening of the Week 16 visit (Visit 10) only for subjects in the deferred treatment arm. 
Subsequent dosing will be taken in the evenings by the subject at approximately the same 
time each day (except for Week 12 and Week 28 doses which must be withheld the night 
before for the predose PK collection at those visits).
Subjects who discontinue therapy in the trial prior to the last scheduled treatment visit should 
have an Early Discontinuation visit and then continue into follow-up visits.
At a minimum, collect the following information when a subject discontinues:
1. The reason the subject discontinued.
2. The date of the last dose of study medications from the trial.
3. The date of the last assessment and/or contact. A follow-up contact (telephone or
visit) will be arranged as appropriate.
4. (Serious) Adverse events.
5. Final Assessments: Every effort should be made to ensure that all procedures and
evaluations scheduled for the Early Discon Visit are performed.
6. Retrieve all study medications from the subject.
7.1.6.4 Follow-Up Visits
At the completion of study therapy (see Section 5.6) subjects will return to the study site for 
follow-up visits at 4, 12, and 24 weeks, after the last dose of study drug.  If a subject
completes 12 weeks of therapy (immediate treatment arm and intensive PK arm), the 4, 12, 
and 24 –week follow-up visits will occur approximately 16, 24, and 36 weeks after Day 1, 
respectively.  Similarly, if a subject completes 24 weeks of therapy (deferred treatment arm), 
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the 4, 12, and 24 –week follow-up visits will occur approximately 28, 36, and 48 weeks after 
Day 1, respectively.
Subjects who discontinue because they have met criteria for virologic failure while on study 
therapy should complete an Early Discontinuation Visit as outlined in the Study Flow Chart  
(Section 6), and return to the study site for follow-up visits at 4, 12, and 24 weeks following 
the confirmation of virologic failure. Subjects who meet the virologic failure criterion of 
relapse (having HCV RNA ≥ LLoQ following end of all study therapy, after becoming 
undetectable (TND) at end of treatment) will return to the study site for follow-up visits at  4, 
12, and 24 weeks as outlined in the Study Flow Chart (Section 6).
Subjects who discontinue for reasons other than virologic failure should complete an Early 
Discontinuation Visit as outlined in the Study Flow Chart and return to the study site for 
follow-up visits at 4, 12, and 24 weeks following the discontinuation of treatment.
Follow-up after Trial Completion 
All subjects who have taken at least one dose of MK-5172 or MK-8742 will be asked to 
consent to a follow-up protocol (MK-5172 Protocol 017, a 3 year follow-up program to study 
efficacy and/or resistance associated variants to any compound used in a MK-5172 treatment 
regimen).  Subjects included in this follow-up protocol may include subjects who have 
initiated other HCV treatments i.e. rescue or other clinical trials, subjects who failed therapy 
in this trial who do not want to initiate a new HCV treatment and subjects who achieved viral 
remission during this trial.  Subjects who undergo kidney transplant and either complete or 
discontinue this study will also be followed in PN017.  The purpose of this follow-up 
protocol is to follow resistance associated variants (RAVs) over time and in the case of 
treatment responders, to follow durability of response.  
7.1.6.5 Evaluations of Laboratory Safety Signals
Laboratory safety measurements will be evaluated weekly throughout the study to assess
potential liver safety signals.
If a subject has one or more of the laboratory ECI criteria (Refer section 7.2.3.2) at the last 
dosing visit (Week 12 for immediate treatment arm or intensive PK arm or Week 24 for 
deferred treatment arm), then the subject should return to the site weekly for additional 
monitoring until the values normalize.
7.1.6.6 Trial Unblinding
For emergency unblinding please refer to Section 7.1.4.4.
Unblinding will occur at Week 16 of the study after all data through Week 12 and safety 
follow-up after Week 12 have been completed, data cleaned and queries resolved.  If the 
subject is determined to have received active therapy during the first 12 weeks, the visit at 
Week 16 will be the FU 4 visit and those study procedures should be followed.  If the subject 
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was determined to have received placebo during the first 12 weeks, the visit at Week 16 will 
be counted as Visit 11 (Day 1 of active dosing) and those study visits followed.
Assessing and Recording Adverse Events7.2
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have to have a causal relationship with this treatment. An adverse event can therefore be any 
unfavourable and unintended sign (including an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product or protocol -
specified procedure, whether or not considered related to the medicinal product or proto col-
specified procedure.  Any worsening (i.e., any clinically significant adverse change in 
frequency and/or intensity) of a preexisting condition that is temporally associated with the 
use of the Sponsor’s product, is also an adverse event.
Changes resulting from normal growth and development that do not vary significantly in 
frequency or severity from expected levels are not to be considered adverse events.  
Examples of this may include, but are not limited to, teething, typical crying in infants and 
children and onset of menses or menopause occurring at a physiologically appropriate time.
Sponsor's product includes any pharmaceutical product, biological product, device, 
diagnostic agent or protocol-specified procedure, whether investigational (including placebo 
or active comparator medication) or marketed, manufactured by, licensed by, provided by or 
distributed by the Sponsor for human use.
Adverse events may occur during the course of the use of the Sponsor's product in clinical 
trials or within the follow-up period specified by the protocol, or prescribed in clinical 
practice, from overdose (whether accidental or intentional), from abuse and from withdrawal.
Adverse events may also occur in screened subjects during any pre-allocation baseline period 
as a result of a protocol-specified intervention, including washout or discontinuation of usual 
therapy, diet, placebo treatment or a procedure.
All adverse events will be recorded from the time the consent form is signed through 14 days 
following cessation of treatment and at each examination on the Adverse Event case report 
forms/worksheets.  The reporting timeframe for adverse events meeting any serious criteria is 
described in section 7.2.3.1.
7.2.1 Definition of an Overdose for This Protocol and Reporting of Overdose to the 
Sponsor
In this trial, an overdose is any dose higher than:  Any intake in excess of the prescribed dose 
of MK-5172 or MK-8742 per calendar day.
If an adverse event(s) is associated with (“results from”) the overdose of Sponsor's product or
vaccine, the adverse event(s) is reported as a serious adverse event, even if no other 
seriousness criteria are met.
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If a dose of Sponsor's product or vaccine meeting the protocol definition of overdose is taken 
without any associated clinical symptoms or abnormal laboratory results, the overdose is 
reported as a non-serious Event of Clinical Interest (ECI), using the terminology “accidental 
or intentional overdose without adverse effect.”
All reports of overdose with and without an adverse event must be reported within 24 hours 
to the Sponsor either by electronic media or paper.  Sponsor Contact information can be 
found in the Investigator Trial File Binder (or equivalent).
7.2.2 Reporting of Pregnancy and Lactation to the Sponsor
Although pregnancy and lactation are not considered adverse events, it is the responsibility of 
investigators or their designees to report any pregnancy or lactation in a subject 
(spontaneously reported to them), including the pregnancy of a male subject's female partner 
that occurs during the trial or within 14 days of completing the trial.  All subjects and female 
partners of male subjects who become pregnant must be followed to the 
completion/termination of the pregnancy.  Pregnancy outcomes of spontaneous abortion, 
missed abortion, benign hydatidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillbirth must be reported as serious events (Important Medical Events).  If 
the pregnancy continues to term, the outcome (health of infant) must also be reported.
Such events must be reported within 24 hours to the Sponsor either by electronic media or 
paper.  Sponsor Contact information can be found in the Investigator Trial File Binder (or 
equivalent).
7.2.3 Immediate Reporting of Adverse Events to the Sponsor
7.2.3.1 Serious Adverse EventsAdverse Events and Incidents
A serious adverse event is any adverse event occurring at any dose or during any use of 
Sponsor's product that:
● Results in death;
● Is life threatening;
● Results in persistent or significant disability/incapacity;
● Results in or prolongs an existing inpatient hospitalization;
● Is a congenital anomaly/birth defect;
● Is a cancer;
● Is associated with an overdose;
● Is an other important medical event
Refer to Table 10 for additional details regarding each of the above criteria.
Any serious adverse event, or follow up to a serious adverse event, including death due to 
any cause that occurs to any subject from the time the consent is signed through 14 days 
following cessation of treatment or within the established off therapy follow-up period for 
safety described in the protocol, whether or not related to the Sponsor's product, must be 
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reported within 24 hours to the Sponsor either by electronic media or paper.  Sponsor Contact 
information can be found in the Investigator Trial File Binder (or equivalent).
Additionally, any serious adverse event, considered by an investigator who is a qualified 
physician to be related to the Sponsor's product that is brought to the attention of the 
investigator at any time outside of the time period specified in the previous paragraph also 
must be reported immediately to the Sponsor.  
All subjects with serious adverse events must be followed up for outcome.
7.2.3.2 Events of Clinical Interest
Selected non-serious and serious adverse events are also known as Events of Clinical Interest 
(ECI) and must be recorded as such on the Adverse Event case report forms/worksheets and 
reported within 24 hours to the Sponsor either by electronic media or paper.  Sponsor Contact 
information can be found in the Investigator Trial File Binder (or equivalent).
Events of clinical interest for this trial include:
1. an overdose of Sponsor's product, as defined in Section 7.2.1 - Definition of an Overdose
for This Protocol and Reporting of Overdose to the Sponsor, that is not associated with
clinical symptoms or abnormal laboratory results.
2. first instance of ALT or AST>500 IU/L from the initiation of study therapy through 14
days following treatment and not associated with virologic failure*
3. first instance of ALT or AST>3x baseline AND >100 IU/L from the initiation of study
therapy through 14 days following treatment and not associated with virologic failure*
4. first instance of alkaline phosphatase>3x ULN from the initiation of study therapy
through 14 days following treatment and not associated with virologic failure*
*Note: The purpose of the criteria is to specify a threshold of abnormal hepatic tests that
may require an additional evaluation for an underlying etiology. The trial site guidance
for assessment and follow up of these criteria can be found in the Investigator Trial File
Binder (or equivalent).
7.2.3.3 Protocol-Specific Exceptions to Serious Adverse Event Reporting
7.2.4 Evaluating Adverse Events
An investigator who is a qualified physician will evaluate all adverse events with respect to 
the elements outlined in Table 10. The investigator’s assessment of causality is required for 
each adverse event.  Refer to Table 10 for instructions in evaluating adverse events.
03XKX6
Product:  MK-5172 66
Protocol/Amendment No.: 052-04 
MK-5172-052-04 Final Protocol 04-Jun-2014
Table 10 Evaluating Adverse Events
Maximum Mild awareness of sign or symptom, but easily tolerated  (for pediatric trials, awareness of symptom, but easily tolerated)
Intensity Moderate discomfort enough to cause interference with usual activity (for pediatric trials, definitely acting like something is wrong)
Severe incapacitating with inability to work or do usual activity (for pediatric trials, extremely distressed or unable to do usual activities)
Seriousness A serious adverse event (AE) is any adverse event occurring at any dose or during any use of Sponsor's product that:
†Results in death; or
†Is life threatening; or places the subject, in the view of the investigator, at immediate risk of death from the event as it occurred [Note: This does not include an 
adverse event  that, had it occurred in a more severe form, might have caused death.]; or
†Results in a persistent or significant disability/incapacity (substantial disruption of one’s ability to conduct normal life functions); or
†Results in or prolongs an existing inpatient hospitalization (hospitalization is defined as an inpatient admission, regardless of length of stay, even if the 
hospitalization is a precautionary measure for continued observation.   (Note: Hospitalization for an elective procedure to treat a pre-existing condition that has not 
worsened is not a serious adverse event.  A pre-existing condition is a clinical condition that is diagnosed prior to the use of a Merck product and is documented in the 
patient’s medical history.); or
†Is a congenital anomaly/birth defect  (in offspring of subject taking the product regardless of time to diagnosis); or
Is a cancer; or
Is associated with an overdose (whether accidental or intentional).  Any adverse event associated with an overdose is considered a serious adverse event. An 
overdose that is not associated with an adverse event is considered a non-serious event of clinical interest and must be reported within 24 hours.
Other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse event when, 
based upon appropriate medical judgment, the event may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed 
previously (designated above by a †).
Duration Record the start and stop dates of the adverse event.  If less than 1 day, indicate the appropriate length of time and units




Did the Sponsor's product cause the adverse event?   The determination of the likelihood that the Sponsor's product caused the adverse event will be provided by an 
investigator who is a qualified physician.  The investigator’s signed/dated initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done.  This initialed document must be retained for the required regulatory time frame.  The 
criteria below are intended as reference guidelines to assist the investigator in assessing the likelihood of a relationship between the test drug and the adverse event 
based upon the available information.  
The following components are to be used to assess the relationship between the Sponsor's product and the AE; the greater the correlation with the components 
and their respective elements (in number and/or intensity), the more likely the Sponsor's product caused the adverse event:
Exposure Is there evidence that the subject was actually exposed to the Sponsor's product such as:  reliable history, acceptable compliance assessment (pill 
count, diary, etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily specimen?
Time Course Did the AE follow in a reasonable temporal sequence from administration of the Sponsor's product? 
Is the time of onset of the AE compatible with a drug-induced effect (applies to trials with investigational medicinal product)?
Likely Cause Is the AE not reasonably explained by another etiology such as underlying disease, other drug(s)/vaccine(s), or other host or environmental 
factors
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Dechallenge Was the Sponsor's product discontinued or dose/exposure/frequency reduced?
      If yes, did the AE resolve or improve?
           If yes, this is a positive dechallenge.    If no, this is a negative dechallenge.
(Note:  This criterion is not applicable if:  (1) the AE resulted in death or permanent disability; (2) the AE resolved/improved despite 
continuation of the Sponsor's product; (3) the trial is a single-dose drug trial); or (4) Sponsor's product(s) is/are only used one time.)
Rechallenge Was the subject re-exposed to the Sponsor's product in this trial?
      If yes, did the AE recur or worsen?
          If yes, this is a positive rechallenge.    If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death or permanent disability, or (2) the trial is a single-dose drug trial); 
or (3) Sponsor's product(s) is/are used only one time.)
NOTE:  IF A RECHALLENGE IS PLANNED FOR AN ADVERSE EVENT WHICH WAS SERIOUS AND WHICH MAY HAVE BEEN 
CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL 
SIGNIFICANT RISK TO THE SUBJECT THEN THE RECHALLENGE MUST BE APPROVED IN ADVANCE BY THE SPONSOR





Is the clinical/pathological presentation of the AE consistent with previous knowledge regarding the Sponsor's product or drug class
pharmacology or toxicology?
The assessment of relationship will be reported on the case report forms /worksheets by an investigator who is a qualified physician according to his/her best clinical judgment, including 
consideration of the above elements.
Record one of the following: Use the following scale of criteria as guidance (not all criteria must be present to be indicative of a Sponsor's product relationship).
Yes, there is a reasonable 
possibility of Sponsor's product 
relationship.
There is evidence of exposure to the Sponsor's product.  The temporal sequence of the AE onset relative to the administration of the Sponsor's 
product is reasonable.  The AE is more likely explained by the Sponsor's product than by another cause. 
No, there is not a reasonable 
possibility of Sponsor's product 
relationship
Subject did not receive the Sponsor's product OR temporal sequence of the AE onset relative to administration of the Sponsor's product is not 
reasonable OR there is another obvious cause of the AE.  (Also entered for a subject with overdose without an associated AE.)
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7.2.5 Sponsor Responsibility for Reporting Adverse Events
All Adverse Events will be reported to regulatory authorities, IRB/IECs and investigators in 
accordance with all applicable global laws and regulations.
TRIAL GOVERNANCE AND OVERSIGHT7.3
7.3.1 Scientific Advisory Committee
This trial was developed in collaboration with a Scientific Advisory Committee (SAC).  The 
SAC comprises both Sponsor and non-Sponsor scientific experts who provide input with 
respect to trial design, interpretation of trial results and subsequent peer -reviewed scientific 
publications. 
7.3.2 Data Monitoring Committee
To supplement the routine trial monitoring outlined in this protocol, an ext ernal Data 
Monitoring Committee (DMC) will monitor the interim data from this trial.  The voting 
members of the committee are external to the Sponsor.  The members of the DMC must not 
be involved with the trial in any other way (e.g., they cannot be trial investigators) and must 
have no competing interests that could affect their roles with respect to the trial. The DMC 
will include 3-5 clinicians experienced in hepatology and nephrology and 1 external 
statistician; this is in addition to the unblinded trial statistician who will be a non-voting 
member of the committee. 
The DMC will make recommendations to the SPONSOR regarding steps to ensure both 
subject safety and the continued ethical integrity of the trial.  Also, the DMC will review 
interim trial results, consider the overall risk and benefit to trial participants (see Section 
8.2.9 - Interim Analyses) and recommend to the SPONSOR if the trial should continue in 
accordance with the protocol.
Specific details regarding responsibilities and governance, including the roles and 
responsibilities of the various members and the SPONSOR; meeting facilitation; the trial 
governance structure; and requirements for and proper documentation of DMC reports, 
minutes, and recommendations will be described in a separate charter that is reviewed and 
approved by the DMC.  The DMC will monitor the trial at an appropriate frequency, as 
described in the detailed DMC charter.  The DMC will also make recommendations to the 
SPONSOR regarding steps to ensure both subject safety and the continued ethical integrity of 
the trial.
A DMC recommendation will be communicated to the Sponsor as agreed to in the 
Collaboration agreement.
8.0 STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study.  If, after 
the study has begun, changes are made to primary and/or key secondary hypotheses, or the 
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statistical methods related to those hypotheses, then the protocol will be amended (consistent 
with ICH Guideline E-9).  Changes to exploratory or other non-confirmatory analyses made 
after the protocol has been finalized, along with an explanation as to when and why they 
occurred, will be listed in the Clinical Study Report (CSR) for the study.  Post hoc 
exploratory analyses will be clearly identified in the CSR.  No separate Statistical Analysis 
Plan (SAP) will be issued for this study.
The first analysis will contain SVR4 and SVR12 from the immediate treatment and the 
intensive PK arms and EOT HCV RNA result from the deferred treatment arm; safety 
analysis will include a comparison of on-treatment safety in immediate vs. deferred treatment 
group and a summary for the immediate treatment arm on safety parameters and adverse 
events during the study therapy period or within 14 days after discontinuing study therapy.
The second analysis will include SVR24 from the immediate treatment arm and the intensive 
PK arm, SVR4, SVR12 and SVR24 from the deferred treatment arm, and SVR12 and SVR24 for 
all treatment arms combined; safety will contain the summary on safety parameters and 
adverse events during the study therapy period or within 14 days after discontinuing study 
therapy for the deferred treatment arm and for all three arms combined.
Statistical Analysis Plan Summary8.1
This section contains a brief summary of the statistical analyses for this trial. Full detail is in 
the Statistical Analysis Plan (SAP) (Section 8.2).
8.1.1 Efficacy Analysis
The primary efficacy endpoints, primary analysis population, and statistical methods that will 
be employed for the efficacy analyses are presented in Table 11 below.
Table 11 Summary of Analysis Strategy for Key Efficacy Endpoints
Endpoint/Variable











†The mFAS population is a subset of the subjects in the immediate treatment and the intensive PK arms
with exclusion of subjects who fail to receive at least one dose of study treatment and subjects with 
missing data due to death or early discontinuation from the study with reasons unrelated to their responses 
to the HCV treatment.
‡ TRD=F: Treatment-Related Discontinuation = Failure (missing values due to death with reasons related 
to study drug or liver disease, and missing values due to premature study discontinuations with treatment 
related reasons such as, clinical or laboratory adverse event related to the study drug, or lack of efficacy are
considered as failures thereafter )
Additional details provided in Section 8.2.
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The primary hypothesis is that patients treated with MK-5172 + MK-8742 for 12 weeks will 
achieve a SVR12 rate higher than the reference SVR12 rate of 45%. The hypothesis will be 
evaluated within the subjects of the immediate treatment and the intensive PK arms, and it
will be tested at two-sided significant level (type-I error) of 0.05. A 95% asymptotic (Wald) 
confidence interval (CI) will also be constructed for the SVR12 rate.
Several considerations led us to choose a reference SVR of 45% for this study:
(1) IFN mono-therapy is recommended for HCV-infected patients with CKD stages 3-5 who
are on or not yet on maintenance dialysis therapy [19]. The meta-analyses, conducted by
Fabrizi et al, revealed a summary SVR24 of 39% (CI 32%-46%) [20].
(2) Given the substantial variation in the GT1 proportion of the studies (ranging from 0 to 1)
in the Fabrizi meta-analyses, a Bayesian logistic regression model for SVR was used to
account for the variation of GT1 proportions. Twenty studies with GT1 proportion were
identified from the Fabrizi paper and included in the re-analysis. Non-informative priors
were used for the Bayesian random-effect model containing a random intercept and a fixed-
effect of GT1 proportion. The model predicts that, if the studies had enrolled 100% GT1, the
posterior probability/confidence that the true overall population mean for SVR rate would
have been at most 45% is about 0.90.
(3) A SVR of approximately 40% was observed in a large study of PEG-IFN/RBV in 3,070
HCV GT1 patients without renal disease conducted in the United States [28]. The SVR
response of patients with CKD stage 4-5 is not expected to be higher than that of the general
HCV population without renal disease.
8.1.2 Safety Analysis
The All-Subjects-as-Treated population will be employed for safety analyses. For this 
protocol, the proportion of subjects who experience the following adverse events during the 
study treatment period will be estimated for each arm: adverse events of elevated laboratory 
values that are reported as ECIs described in section 7.2.3.2 (Tier 1 events). The Tier 1 
events rates of the immediate treatment arm will be compared to those of the placebo 
treatment period of the deferred treatment arm. P-values and 95% confidence intervals for 
between-treatment differences will be calculated using the Miettinen and Nurminen method
[29].
Safety and tolerability will be carefully monitored throughout the study by the SPONSOR (or 
designee) in accordance with standard procedures and also by an external Data Monitoring 
Committee (DMC).
8.1.3 Power and Sample Size
This study will randomize 105 subjects into the immediate treatment arm and 105 subjects 
into the deferred treatment group. In addition, 10 subjects will be enrolled as intensive PK 
cohort. The primary hypothesis will be evaluated within the subjects of the immediate 
treatment and the intensive PK arms (n=115). It would have at least 95% power to 
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demonstrate that the SVR12 rate of MK-5172 + MK-8742 is higher than the reference SVR12
rate of 45% at an overall one-sided 0.025 α-level, if the true SVR12 rate of MK-5172 + MK-
8742 is about 65%. The power and sample size are based on the assumption that 
approximately 10% of the randomized subjects would have missing SVR12 rate due to death 
or early discontinuation from study with reasons unrelated to their responses to the HCV 
treatment and will be excluded from the mFAS population (i.e. assuming the mFAS 
population size of 103 subjects).  The calculation is based on SAS PROC POWER based on z-
test using the normal approximation to the binomial distribution. 
Statistical Analysis Plan8.2
8.2.1 Responsibility for Analyses/In-House Blinding
The statistical analyses of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the SPONSOR.  Certain specific analyses such as PK, 
pharmacogenetics and resistance will be the responsibility of the appropriate departments of 
the SPONSOR.
Subjects in the immediate and deferred treatment arms, and corresponding site personnel and 
investigators will remain blinded to the treatment groups for the first 12 weeks of treatment 
period under in-house blinding procedures. The second 12 weeks of active treatment period 
for the deferred arm will be conducted as an open-label study. The database will be 
unblinded at Week 16 visit for the immediate and the deferred treatment arm. Note that the
Week 16 visit takes place 16 weeks after randomization, and it is also the FU WK4 visit for 
the immediate treatment arm.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study treatment assignment.  Randomization will be implemented by an IVRS. (Please note, 
the 10 subjects assigned to the Intensive PK Arm will be open-label)
Pharmacokinetic (PK) measurements will be conducted in support of PK evaluations. 
Additionally, a small team as specified in a separate Modeling and Simulation (M&S) 
Modeling Analysis Plan, and who are separate from the study team, will be unblinded for the 
purpose of preparing the pharmacokinetic analyses. No PK data or results from the PK 
analyses will be shared with the study team, and the unblinded group will not be members of 
the study team. 
During the course of the trial, periodic safety analyses will be conducted. An external data 
monitoring committee (DMC) will be established to safeguard the interests of trial 
participants, to provide ongoing review of those safety data and to monitor the overall 
conduct of the trial. 
For the first 12 weeks of treatment period, treatment-level and patient-level safety results will
be provided by the unblinded statistician to DMC. Limited additional SPONSOR personnel 
may be unblinded to the treatment level results of these reviews, if required, in order to act 
on the recommendations of the DMC. The extent to which individuals are un blinded with 
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respect to results of interim reviews will be documented by the unblinded statistician. The 
unblinded statistician will not be involved in any discussions regarding modifications to the 
protocol, statistical methods, identification of protocol violators, or data validation efforts 
after the interim analyses.
The DMC will perform periodic reviews of safety data in order to protect subject welfare and 
preserve study integrity. There will be no enrollment pause in the study during these reviews. 
The DMC is to recommend to the SPONSOR whether the nature, frequency, and severity of 
adverse effects associated with study treatment warrant the early termination of the study in 
the best interests of the participants, whether the study should continue as planned, or the 
study should continue with modifications. While the DMC will be asked to advise 
SPONSOR regarding future conduct of the study, including possible early study termination, 
SPONSOR retains final decision-making authority on all aspects of the study. Additional 
logistical details will be provided in the external DMC Charter.
8.2.2 Hypotheses/Estimation
Objectives and hypotheses of the study are stated in Section 3.0.
8.2.3 Analysis Endpoints
Efficacy and safety endpoints that will be evaluated are listed in the following sections.
8.2.3.1 Efficacy/Pharmacokinetic Endpoints
8.2.3.1.1 Efficacy Endpoints
An initial description of efficacy measures is provided in Section 4.2.3.1.
The primary efficacy endpoint will be the SVR12 rate of the subjects in the immediate 
treatment and the intensive PK arms. 
The secondary efficacy endpoints are
1. The SVR4 and SVR24 rates of the subjects within the immediate treatment and the
intensive PK arms.
2. The SVR4, SVR12, and SVR24 rates in the deferred treatment arm following the end of all
active study therapy.
3. The SVR4, SVR12, and SVR24 rates following the end of all active study therapy for all
treatment arms combined.
4. The emergence of viral resistant to MK-5172 and MK-8742 when administered as a
combination regimen
5. Proportion of achieving TND, TD(u), and TD(q) at EOT
8.2.3.1.2 Pharmacokinetic Endpoints
An initial description of efficacy measures is provided in Section 4.2.3.3.
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The PK endpoints for MK-5172, MK-8742 are AUC0-24, C2hr and Ctrough
8.2.3.1.3 Exploratory Endpoints
1. The level of biomarkers (e.g., proteins and metabolite production), that may be
predictive of tolerability of study drugs and virologic response to MK-5172 in
combination with MK-8742
2. Change from baseline in health-related quality of life for each of the SF-36v2 eight
health domain scores (Physical Functioning, Role Limitations-Physical, Bodily Pain,
General Health, Vitality, Social Functioning, Role Limitations-Emotional, and Mental
Health), and the Physical Component Summary (PCS) and Mental Component
Summary (MCS) score
3. Change from baseline in Serum cryoglobulin level, rheumatoid factor, and C4
Complement in subjects with Cryoglobulinemia
8.2.3.2 Safety Endpoints
An initial description of safety measures is provided in Section 4.2.3.2.
The analysis of safety results will follow a tiered approach. The tiers differ with respect to 
the analyses that will be performed. Safety parameters or adverse events of special interest 
that are identified a priori constitute Tier 1 safety endpoints that will be subject to inferential 
testing for statistical significance with p-values and 95% confidence intervals provided for 
between-group comparisons. Other safety parameters will be considered Tier 2 or Tier 3. 
Tier 2 parameters (requires that at least 4 subjects in each treatment group exhibit the event) 
will be assessed via point estimates with 95% confidence intervals provided for between-
group comparisons; only point estimates by treatment group are provided for Tier 3 safety 
parameters.
For this protocol, the Tier 1 safety parameters and adverse events are the proportion of 
subjects with adverse events of the following types at any time during the study therapy 
period: adverse events of elevated laboratory values that are reported as ECIs described in 
section 7.2.3.2.
The following are Tier 2 safety parameters and adverse events: 
1. Proportion of subjects with adverse experiences of the following types at any time during
the study therapy period:  (1) at least one adverse event; (2) a drug-related adverse event;
(3) a serious adverse event; (4) a renal serious adverse event; (5) a serious and drug-
related adverse event; (6) an adverse event leading to discontinuation from treatment; and
(7) renal disease progression (defined as increasing dialysis frequency in subjects who
were on hemodialysis at baseline, initiation of maintenance hemodialysis in subjects who
were not on hemodialysis at baseline, or progressive increase in CKD stages).
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2. Change from baseline in serum creatinine and BUN, estimated GFR at the end of active
study therapy for the immediate treatment arm and at the end of placebo treatment for the
deferred treatment arm for CKD 4-5 subjects who are not receiving HD at baseline.
Serious adverse experiences will continue to be collected throughout the study.
For all subjects in the deferred treatment arm, safety results during the period of receiving 
active study therapy will be summarized and described.
8.2.4 Analysis Populations
8.2.4.1 Efficacy Analysis Populations
The Modified Full Analysis Set (mFAS) population will serve as the primary population for 
the analysis of efficacy data in this study. The mFAS population is a subset of the subjects, 
who are randomized to the immediate treatment arm or who are assigned to the intensive PK 
arm, with subjects excluded for the following reasons:
• failure to receive at least one dose of study treatment
• missing data due to death with reasons unrelated to study drug or reasons other than
liver disease
• missing data due to study discontinuation with reasons unrelated to progression of
liver disease, study drug and their responses to the HCV treatment.
All subjects who return for follow-up visits will be included in the corresponding SVR 
analysis, regardless of the length of treatment received or reason for discontinuation.
A supportive analysis using the Per-Protocol (PP) population will be performed for the 
primary (SVR12) and key secondary efficacy endpoints (SVR4 and SVR24). The PP 
population is a subset of the mFAS population. The PP population excludes subjects due to 
important deviations from the protocol that may substantially affect the results of the primary 
and key secondary efficacy endpoints. Potential violations that may result in the exclusion of 
a subject from the PP population include:
 Violations of  specific inclusion/exclusion criteria:
 The subject is infected with a non-GT 1 HCV infection at entry or during the
course of the study, including a mixed GT infection (with a non-GT 1) or a non-
typeable genotype
 The subject met criteria for futility, virologic breakthrough or end of treatment failure but
had undetectable MK-5172 levels at one or more pharmacokinetic sampling timepoints
temporally associated with the failure timepoint
 The subject received concomitant medications that are prohibited due to their potential to
result in a clinically significant lowering of the MK-5172 concentrations including:
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 CYP3A4 inducers such as rifampin, carbamazepine and efavirenz
 P-gp inducers such as St. John's Wort
 Any co-administered medication, currently unidentified, but for which subsequent
clinical DDI data indicate that co-administration with MK-5172 leads to a
clinically significant lowering of MK-5172 concentrations
 Other violations may be identified during the course of data collection and they will be
listed specifically in the CSR
A subject with important deviations from the protocol as described above at randomization 
will be excluded from the PP population.  For subjects with important deviations from the 
protocol as described above during course of the treatment, data obtained subsequent to the 
violation will be excluded from analysis.
The FAS population consists of all randomized subjects who have received at least one dose 
of study treatment. This is one of the supportive analysis populations in this study.
Subjects will be included in the treatment group to which they are randomized for the 
analysis of efficacy data using mFAS, FAS, and PP populations.  Details on the approach to 
handling missing data are provided in Section 8.2.5 Statistical Methods.
8.2.4.2 Safety Analysis Populations
The All Subjects as Treated (ASaT) population will be used for the analysis of safety data in 
this study.  The ASaT population consists of all randomized subjects who received at least 
one dose of study treatment. Subjects will be included in the treatment group corresponding 
to the study treatment they actually received for the analysis of safety data using the ASaT 
population.  For most subjects this will be the treatment group to which they are randomized.  
Subjects who take incorrect study treatment for the entire treatment period will be included in 
the treatment group corresponding to the study treatment they actually received.
At least one laboratory or vital sign measurement obtained subsequent to at least one dose of 
study treatment is required for inclusion in the analysis of each specific parameter.  To assess 
change from baseline, a baseline measurement is also required. 
Details on the approach to handling missing data for safety analyses are provided in Section 
8.2.5 Statistical Methods.
8.2.5 Statistical Methods
The approach to handling missing data is described in Section 8.2.5.1. Statistical testing and 
inference for safety analyses are described in Section 8.2.5.2. Unless otherwise stated, all 
statistical tests will be conducted at the α=0.05 (2-sided) level. 
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8.2.5.1 Statistical Methods for Efficacy Analyses
Missing values
A missing data point for a given study visit may be due to any one of the following reasons: a 
visit occurred but data were not collected or were unusable; a visit did not occur; and a 
subject discontinued from the study before reaching the visit. Subjects who prematurely 
discontinued the assigned treatment should remain in the study for the follow-up, if possible.
The HCV RNA outcome is categorized as TND, TD(u), and TD(q). There are 3 types of 
missing data handled by different approaches.
1. Intermittent missing: If a missing data point is immediately preceded and followed by
non-missing HCV RNA outcomes, the missing value would be imputed to the worse
outcome of the two. For example, if a missing data point is preceded by TD(q) and
followed by TD(u) or TND, then the missing value would be imputed as TD(q); if a
missing data point is preceded by TD(u) and followed by  TND, then the missing value
would be imputed as TD(u); when a missing value is flanked by two TND, then the
missing value would be imputed as TND.
2. Non-intermittent missing related to the study drug: For missing values due to death with
reasons related to study drug or liver disease, and missing values due to premature study
discontinuations with treatment related reasons such as, progression of liver disease,
clinical or laboratory adverse event related to the study drug, or lack of efficacy (e.g.
discontinuation from the study following a confirmed HCV RNA TD(q)), the missing
values will be considered as treatment failures and thereafter.
3. Non-intermittent missing unrelated to the study drug: For missing data due to death with
reasons unrelated to study drug or reasons other than liver disease, and due to premature
study discontinuations with reasons unrelated to treatment such as loss to follow-up,
protocol violation, patient withdrew consent, etc., the missingness mechanism is unlikely
to related to patients’ response to the HCV treatment, and therefore the missing at
random (MAR) assumption is plausible. The approaches to address this type of missing
data depend on the analytical strategy, and they are described in the following sections.
In addition, a missing baseline/Day1 HCV RNA result will be replaced with a screening 
result, if available. Missing values in the health-related quality of life data will not be 
imputed.
SVR12 rate (proportion of achieving SVR12)
The study hypothesis is that patients treated with MK-5172 + MK-8742 for 12 weeks will 
achieve a SVR12 rate higher than the reference SVR12 rate of 45%. Correspondingly, the 
null hypothesis (H0) is that SVR12 rate ≤ 45%; the alternative hypothesis (Ha) is that SVR12
rate  > 45%. A treatment effect is established statistically by showing that the lower bound of 
the two-sided 95% confidence interval for SVR12 rate > 45%. A Wald test will be performed 
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at two-sided significant level (type-I error) of 0.05. This hypothesis will be evaluated 
primarily in the combined immediate treatment and intensive PK arms.
Primary approach
The SVR12 rate is estimated by the ratio of the number of subjects achieving SVR12 versus 
the number of subjects in the mFAS population, that is, the proportion of subjects with 
SVR12 in the mFAS. A two-sided 95% asymptotic (Wald) confidence interval will be calculated.
Under the assumption of missing completely at random (MCAR), the mFAS population 
excludes subjects who did not experience virologic failure, but prematurely withdraw from 
study due to reasons not related to the study drug (i.e., the subjects with the type 3 missing 
value) . Note that subjects with documented virologic failure during the treatment or follow-
up period, even if they withdrew prematurely due to reasons not related to study drug, are 
included in the mFAS population and classified as failures.  
Secondary approaches
The SVR12 rate will also be estimated in the PP population as supportive analysis, using the 
approach described above.
Sensitivity analysis will be conducted in the FAS population to address the robustness of the 
study conclusion to the management of the type 3 missing information. In this analysis, the 
type 3 missing will be imputed as failure. The SVR12 rate is estimated by the ratio of the 
number of subjects achieving SVR12 versus the number of subjects in the FAS population, 
that is, the proportion of subjects with SVR12 in the FAS. However, it is useful to note that 
this approach invokes maximal stress to the robustness of the study results and puts a bound 
on the extent of the impact of the type 3 missing information.
Other efficacy endpoints
The EOT HCV RNA for the immediate treatment and intensive PK arms and for the deferred
treatment arm will be summarized as proportion according to the categories of TND, TD(u), 
and TD(q). Table 12 summarizes the key efficacy analyses.
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SVR12  rate P Wald test
(95% asymptotic CI)
mFAS TRD=F‡
(i.e., M=F‡ for type 2
DAO ‡ for type 3
SVR12  rate S Wald test
(95% asymptotic CI)
FAS M=F for type 2 and  
type 3
SVR12  rate S Wald test
(95% asymptotic CI)
PP TRD=F
(i.e., M=F for type 2
DAO for type 3)
Secondary
SVR4  and SVR24 rates P 95% asymptotic CI mFAS TRD=F
(i.e., M=F for type 2
DAO for type 3
SVR4  and SVR24 rates S 95% asymptotic CI FAS M=F for type 2 and  
type 3
SVR4  and SVR24 rates S 95% asymptotic CI PP TRD=F
(i.e., M=F for type 2
DAO  for type 3
† P=Primary approach; S=Secondary approach.
‡ Imputation for specific missing values described in Section 8.2.5.1
TRD=F is Treatment-Related Discontinuation = Failure;  DAO = Data as observed; M=F is missing=failure
Subject Virologic Failure: Non-response, Rebound, Breakthrough, and Relapse 
Summary statistics will be provided to describe the rates of occurrence of subject virologic 
non-response, rebound, breakthrough, and relapse.  Definitions for subject virologic non-
response, rebound, breakthrough, and relapse are in Section 4.2.3.1.1.2
8.2.5.2 Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
ECIs, adverse events and laboratory parameters.
The analysis of safety results will follow a tiered approach (Table 13).  The tiers differ with 
respect to the analyses that will be performed.  Safety parameters or adverse experiences of 
special interest that are identified a priori constitute “Tier 1” safety endpoints that will be 
subject to inferential testing for statistical significance with p-values and 95% confidence 
intervals provided for between-group comparisons.  Other safety parameters will be 
considered Tier 2 or Tier 3.  Tier 2 parameters will be assessed via point estimates with 95% 
confidence intervals provided for between-group comparisons; only point estimates by 
treatment group are provided for Tier 3 safety parameters.
Adverse experiences (specific terms as well as system organ class terms) and predefined 
limits of change in laboratory and vital signs that are not pre-specified as endpoints of special 
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interest will be classified as belonging to "Tier 2" or "Tier 3", based on the number of events 
observed. Membership in Tier 2 requires that at least 4 patients in any treatment group 
exhibit the event; all other adverse experiences and predefined limits of change will belong to 
Tier 3. 
The threshold of at least 4 events was chosen because the 95% confidence interval for the 
between-group difference in percent incidence will always include zero when treatment 
groups of equal size each have less than 4 events and thus would add little to the 
interpretation of potentially meaningful differences. Because many 95% confidence intervals 
may be provided without adjustment for multiplicity, the confidence intervals should be 
regarded as a helpful descriptive measure to be used in review, not a formal method for 
assessing the statistical significance of the between-group differences in adverse experiences 
and predefined limits of change. 
Changes from baseline in laboratory and vital signs that are not pre-specified as endpoints of 
special interest will be considered Tier 3 safety parameters. Summary statistics for baseline, 
on-treatment, and change from baseline values will be provided in table format.
Values for missing safety laboratory data or missing vital signs will not be imputed; 
however, a missing Baseline/Day 1 result will be replaced with a screening result, if 
available. If no pretreatment laboratory value is available, the Baseline/Day 1 value will be 
assumed to be normal (i.e., no grade [Grade 0]) for the summary of graded laboratory 
abnormalities. Missing values will be handled using the Data-As-Observed (DAO) approach.
For this protocol, the primary safety analysis will compare the safety data in the immediate 
treatment arm during the treatment period to those of the deferred treatment arm during the 
placebo treatment period. For categorical data, p-values (Tier 1 only) and 95% confidence 
intervals (Tier 1 and Tier 2) will be provided for between-treatment differences in the 
percentage of patients with events; these analyses will be performed using the Miettinen and 
Nurminen method [29], an unconditional, asymptotic method. For continuous data (as Tier 
2), 95% confidence intervals will be provided for differences in the group means using 
asymptotic method
The safety parameters and adverse events during the active study therapy period, or within 14 
days after discontinuing active study therapy will also be summarized for the combined
immediate treatment and intensive PK arms, and for the differed treatment arm. 95% CI will 
be provided for the proportion of subjects with the Tier 1 and Tier 2 adverse events.
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Table 13 Analysis Strategy for Safety Parameters 
Safety Tier Safety Endpoint† p-Value










Any AE X X
Any Serious AE X X
Any Drug-Related AE X X
Any Serious and Drug-Related AE X X
Renal SAE





Renal disease progression X X
Change from Baseline Results (serum 
creatinine, BUN, and estimated GFR) 
X X
Specific AEs, SOCs, or PDLCs‡ (incidence ≥4 
of patients in one of the treatment groups)
X X
Tier 3
Specific AEs, SOCs, or PDLCs‡ (incidence < 4 
of patients in one of the treatment groups)
X
Change from Baseline Results (Labs and Vital 
Signs)
X
† Adverse events references refer to both Clinical and Laboratory AEs.
‡ Includes only those endpoints not pre-specified as Tier 1 or not already pre-specifed as Tier-2 
endpoints.
Note: SOC=System Organ Class; PDLC=Pre-Defined Limit of Change; X  = results will be provided.
8.2.5.3 Summaries of Baseline Characteristics, Demographics, and Other Analyses
Demographic and Baseline Characteristics 
The comparability of the treatment groups for each relevant characteristic will be assessed by 
the use of descriptive statistics.  No statistical hypothesis tests will be performed on these 
characteristics.  The number and percentage of subjects screened, randomized, the primary 
reasons for screen failure, and the primary reason for discontinuation will be displayed.  
Demographic variables (e.g., age, gender, and genotype subtype), primary and secondary 
diagnoses, prior and concomitant therapies will be summarized by treatment arm using 
descriptive statistics for continuous or categorical variables, as appropriate.  Summary 
statistics for the baseline efficacy measure (HCV RNA) will also be provided by treatment 
group.
Pharmacokinetic Analyses
Summary statistics for the concentrations of MK-5172 and MK-8742 will be provided for the 
immediate treatment and the intensive PK groups. PK/PD analysis may also be performed 
within the intensive PK and evening pre-dose PK cohorts for MK-5172 and MK-8742.
Viral Resistance Measurements
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Viral resistance testing will focus on the entire NS3/4A and NS5A regions for all subjects 
and for those who meet the subject virologic failure criteria (see Section 4.2.3.1.). 
HCV genotyping is conducted using the Versant HCV genotype (LiPA) 2.0 manufactured by
Innogenetics. In the US, the assay is distributed by Siemens.
IL28B Analyses and Other Genetic Analysis
Exploratory descriptive analyses will include demographic and selected baseline 
characteristics by IL28B genotype overall, as well as SVR12 by IL28B genotype by treatment 
arm. Additional genetic analysis may be conducted to identify variations in HLA and ADME 
genes related to liver injury or other safety findings.
Patient-Reported Outcomes Measurement 
Descriptive summary statistics will be provided for the change from baseline scores for each
of the SF-36v2 eight health domains (Physical Functioning, Role Limitations-Physical,
Bodily Pain, General Health, Vitality, Social Functioning, Role Limitations-Emotional, and
Mental Health), and Physical Component Summary (PCS) and Mental Component Summary
(MCS). These analyses will be conducted for the immediate and deferred treatment arms at 
Week 12, Week 28 (deferred treatment arm only), Follow-Up Week 12, and Early 
Discontinuation. Missing data will not be imputed and the analysis will be based on observed 
data only (DAO approach). These analyses will be based on the FAS population. No 
multiplicity adjustment will be applied.
8.2.6 Multiplicity
As there is only a single primary efficacy hypothesis which is being conducted at the one-
sided =0.025 level, no multiplicity adjustment is needed for the primary efficacy analysis.  
The secondary efficacy objectives are estimation objectives, are supportive in nature and 
have no associated hypotheses.  Therefore, no multiplicity adjustment is necessary for the 
secondary efficacy analysis.
8.2.7 Sample Size and Power Calculations
8.2.7.1 Efficacy Analysis
This study will randomize 105 subjects into the immediate treatment arm and 105 subjects 
into the deferred treatment group. In addition, 10 subjects will be enrolled as intensive PK 
cohort. The primary hypothesis will be evaluated within the subjects of the immediate 
treatment and the intensive PK arms (n=115). It would have at least 95% power to 
demonstrate that the SVR12 rate of MK-5172 + MK-8742 is higher than the reference SVR12
rate of 45% at an overall one-sided 0.025 α-level, if the true SVR12 rate of MK-5172 + MK-
8742 is about 65%. The power and sample size are based on the assumption that 
approximately 10% of the randomized subjects would have missing SVR12 rate due to death 
or early discontinuation from study with reasons unrelated to their responses to the HCV 
treatment and will be excluded from the mFAS population (i.e. assuming the mFAS 
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population size of 103 subjects).  The calculation is based on SAS PROC POWER based on z-
test using the normal approximation to the binomial distribution. Table 14 summarizes such
power calculations for the primary efficacy analysis under various assumptions about the true 
SVR12 rate of MK-5172 + MK-8742.
Table 14 Power Calculations for the Primary Hypothesis Test Within the Subjects of the 
Immediate Treatment and the Intensive PK Arms






The primary safety analysis will compare the safety data in the immediate treatment arm 
during the treatment period to those of the deferred treatment arm during the placebo period. 
Table 15 summarizes the power to detect an adverse event rate difference between the 
treatment arms using a 2-sided 5% alpha level, if the immediate treatment arm has a two-fold 
or three-fold increment in adverse event rate. These calculations are under various 
assumptions about the true adverse event rate in the deferred treatment arm, and assume 105 
subjects in each arm.
Table 16 gives the power to rule out a 50% or 100% higher adverse event rate in the 
immediate treatment arm at a 1-sided 2.5% alpha level, if the event rates are the same in both the 
immediate and deferred treatment arms. The calculations assume 105 subjects in each arm and 
are based on an asymptotic method proposed by Farrington and Manning (1990).
Table 15 Power to Detect Difference in Adverse Event Rate
True event rate in 
the deferred arm while 
placebo administered
True event rate in 
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Table 16 Power to Rule Out a 50% or 100% Higher Adverse Event Rate in the Immediate 
Treatment Arm, Assuming Both Arms Have the Same Event Rate
True event rate in  both 
immediate and deferred arms 
Power  to rule out a 50% 
increase in the immediate 
treatment arm
Power  to rule out a 100% 






30% 66% > 99%
8.2.8 Subgroup Analyses and Effects of Baseline Factors
To determine whether the response is consistent across various subgroups, the SVR12 rate 
with 95% CIs will be estimated within each category of the following classification variables:
Sex (female, male)
GT: (1a vs 1 non-a)
IL28B CC genotype vs. non-CC genotype
HCV RNA at baseline, low (≤ 800,000 IU/mL) versus high (> 800,000 IU/mL)
Stage of fibrosis (Non-cirrhotic vs. Cirrhotic)
Dialysis (yes vs. no)
Diabetes (yes vs. no)
 CKD stage (4 and 5)
 Prior IFN or PEG-IFN + Ribavirin treatment response (Treatment naïve, Relapser, Partial
responder, and Null Responder)
The consistency of the efficacy response will be assessed descriptively using summary 
statistics for each category of the classification variables listed above.
In addition, Safety comparison between the immediate and differed treatment arms will also 
be conducted according to the subgroups of on dialysis vs. not on dialysis, diabetics vs. non-
diabetics, and CKD stages (4 and 5).
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8.2.9 Interim Analyses
No formal interim analyses are planned for this study. During the course of the trial, periodic 
safety analyses will be conducted for the accruing data and will be reviewed by an external 
DMC at regular intervals to ensure the safety of the patients participating in the clinical trial.
8.2.10 Compliance (Medical Adherence)
In this study, as part of the routine recording of the amount of study treatment taken by each 
subject, the number of tablets remaining in study packaging will be counted, reviewe d, and 
recorded at regular intervals.  These results will be used to calculate subject compliance.
A day within the study will be considered an “On-Therapy” day if the subject takes the MK-
5172 100mg/MK-8742 50mg or the Placebo tablet(s). The “Number of Days Should be on 
Therapy” is the total number of days from randomization to the date of the last dose of study 
medication for that subject. Note, the date of the last dose of study medication would be the 
last scheduled day for treatment administration for subject who completed the assigned 
treatment.
For each subject, percent compliance will then be calculated using the following formula:
Therapyon beShouldDaysofNumber 
Therapyon DaysofNumber 
CompliancePercent  x 100.
Summary statistics will be provided on percent compliance.
9.0 LABELING, PACKAGING, STORAGE AND RETURN OF CLINICAL 
SUPPLIES
Investigational Product9.1
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of 
investigational product in accordance with the protocol and any applicable laws and 
regulations.
Clinical Supplies will be provided by the Sponsor as summarized in Table 17.
Clinical supplies will be packaged to support enrollment and replacement subjects as 
required.  When a replacement subject is required, the Sponsor or designee needs to be 
contacted prior to dosing the replacement supplies.
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Table 17 Product Descriptions






MK-5172 100mg / MK8742 50mg Tablet
MK-5172 0mg / MK8742 0mg Tablet
All placebos were created by the Sponsor to match the active product.
The single entity tablet formulations will be used in the Intensive PK arm and for the first 12 
weeks of dosing in the Immediate Treatment and Deferred Treatment arms.  The fixed dose 
combination formulation will be used for Week 16 to Week 28 dosing in the Deferred 
Treatment arm.
Packaging and Labeling Information9.2
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirements.
Subjects will receive open label and blinded monthly finished good bottles. No kitting is 
required.
Clinical Supplies Disclosure9.3
Part of the trial is open-label; therefore, the subject, the trial site personnel, the Sponsor 
and/or designee are not blinded. Treatment (name, strength or potency) is included in the 
label text; random code/disclosure envelopes or lists are not provided.
The central electronic randomization system (IVRS/IWRS) should be used in order to 
unblind subjects and to unmask treatment identity. The Sponsor will not provide random 
code/disclosure envelopes or lists with the clinical supplies.
Treatment identification information is to be unmasked ONLY if necessary for the welfare of 
the subject.  Every effort should be made not to unblind the subject unless necessary. 
In the event that unblinding has occurred, the circumstances around the unblinding (e.g., date 
and reason) must be documented promptly, and the Sponsor Clinical Director notified as 
soon as possible.  Only the principal investigator or delegate and the respective subject’s 
code should be unblinded.  Trial site personnel and Sponsor personnel directly associated 
with the conduct of the trial should not be unblinded.
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Storage and Handling Requirements9.4
Clinical supplies must be stored in a secure, limited-access location under the storage 
conditions specified on the label.  
Receipt and dispensing of trial medication must be recorded by an authorized person at the 
trial site.
Clinical supplies may not be used for any purpose other than that stated in the protocol.
Returns and Reconciliation9.5
The investigator is responsible for keeping accurate records of the clinical s upplies received 
from the Sponsor or designee, the amount dispensed to and returned by the subjects and the 
amount remaining at the conclusion of the trial. 
For all trial sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return.
Standard Policies9.6
Trial site personnel will have access to a central electronic randomization system 
(IVRS/IWRS system) to allocate subjects, to assign treatment to subjects and to manage the 
distribution of clinical supplies. Each person accessing the IVRS system must be assigned an 
individual unique PIN.  They must use only their assigned PIN to access the system, and they 
must not share their assigned PIN with anyone.
10.0 ADMINISTRATIVE AND REGULATORY DETAILS
Confidentiality10.1
10.1.1 Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (IRB/ERC) or similar 
or expert committee; affiliated institution and employees, only under an appropriate 
understanding of confidentiality with such board or committee, affiliated institution and 
employees.  Data generated by this trial will be considered confidential by the investigator, 
except to the extent that it is included in a publication as provided in the Publications section 
of this protocol.
10.1.2 Confidentiality of Subject Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/ERC, or regulatory authority representatives may consult and/or copy trial documents in 
order to verify worksheet/case report form data. By signing the consent form, the subject 
agrees to this process.  If trial documents will be photocopied during the process of verifying 
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worksheet/case report form information, the subject will be identified by unique code only; 
full names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all subject data used and disclosed in 
connection with this trial in accordance with all applicable privacy laws, rules and 
regulations.
10.1.3 Confidentiality of Investigator Information
By signing this protocol, the investigator recognizes that certain personal identifying 
information with respect to the investigator, and all subinvestigators and trial site personnel, 
may be used and disclosed for trial management purposes, as part of a regulatory 
submissions, and as required by law.  This information may include:
1. name, address, telephone number and e-mail address;
2. hospital or clinic address and telephone number;
3. curriculum vitae or other summary of qualifications and credentials; and
4. other professional documentation.
Consistent with the purposes described above, this information may be transmitted to the 
Sponsor, and subsidiaries, affiliates and agents of the Sponsor, in your country and other 
countries, including countries that do not have laws protecting such information.  
Additionally, the investigator’s name and business contact information may be included 
when reporting certain serious adverse events to regulatory authorities or to other 
investigators.  By signing this protocol, the investigator expressly consents to these uses and 
disclosures.
If this is a multicenter trial, in order to facilitate contact between investigators, the Sponsor 
may share an investigator’s name and contact information with other participating 
investigators upon request.
10.1.4 Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC member that 
reviews and approves this trial.  The Sponsor is also required to document that each IRB/IEC 
meets regulatory and ICH GCP requirements by requesting and maintaining records of the 
names and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by those agencies.
Compliance with Financial Disclosure Requirements10.2
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54).  It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
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Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility to comply with any such request.  
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
the Sponsor or through a secure password-protected electronic portal provided by the 
Sponsor.  The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Compliance with Law, Audit and Debarment10.3
By signing this protocol, the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of Good 
Clinical Practice (e.g., International Conference on Harmonizat ion of Technical 
Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice: 
Consolidated Guideline and other generally accepted standards of good clinical practice); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by Merck, is provided in Section 12.1 -
Merck Code of Conduct for Clinical Trials.
The investigator also agrees to allow monitoring, audits, IRB/ERC review and regulatory 
authority inspection of trial-related documents and procedures and provide for direct access 
to all trial-related source data and documents.
The investigator agrees not to seek reimbursement from subjects, their insurance providers or 
from government programs for procedures included as part of the trial reimbursed to the 
investigator by the Sponsor.
The investigator shall prepare and maintain complete and accurate trial documentation in 
compliance with Good Clinical Practice standards and applicable federal, state and local 
laws, rules and regulations; and, for each subject participating in the trial, provide all data, 
and, upon completion or termination of the clinical trial, submit any other reports to the 
Sponsor as required by this protocol or as otherwise required pursuant to any agreement with 
the Sponsor.
Trial documentation will be promptly and fully disclosed to the Sponsor by the inv estigator 
upon request and also shall be made available at the trial site upon request for inspection, 
copying, review and audit at reasonable times by representatives of the Sponsor or any 
regulatory authorities.  The investigator agrees to promptly take any reasonable steps that are 
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requested by the Sponsor as a result of an audit to cure deficiencies in the trial documentation 
and worksheets/case report forms.
The investigator must maintain copies of all documentation and records relating to the 
conduct of the trial in compliance with all applicable legal and regulatory requirements.  This 
documentation includes, but is not limited to, the protocol, worksheets/case report forms, 
advertising for subject participation, adverse event reports, subject source data, 
correspondence with regulatory authorities and IRBs/ERCs, consent forms, investigator’s 
curricula vitae, monitor visit logs, laboratory reference ranges, laboratory certification or 
quality control procedures and laboratory director curriculum vitae.  By signing this protocol, 
the investigator agrees that documentation shall be retained until at least 2 years after the last 
approval of a marketing application in an ICH region or until there are no pending or 
contemplated marketing applications in an ICH region or until at least 2 years have elapsed 
since the formal discontinuation of clinical development of the investigational product.  
Because the clinical development and marketing application process is variable, it is 
anticipated that the retention period can be up to 15 years or longer after protocol database 
lock. The Sponsor will determine the minimum retention period and notify the investigator 
when documents may be destroyed.  The sponsor also recognizes that documents may need 
to be retained for a longer period if required by local regulatory requirements. All trial 
documents shall be made available if required by relevant regulatory authorities. The 
investigator must consult with and obtain written approval by the Sponsor prior to discarding 
trial and/or subject files.  
ICH Good Clinical Practice guidelines recommend that the investigator inform the subject’s 
primary physician about the subject’s participation in the trial if the subject has a primary 
physician and if the subject agrees to the primary physician being informed.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this trial.
Persons debarred from conducting or working on clinical trials by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor’s trials.  The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the trial is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
In the event the Sponsor prematurely terminates a particular trial site, the Sponsor will 
promptly notify that trial site’s IRB/IEC.
According to European legislation, a Sponsor must designate an overall coordinating 
investigator for a multi-center trial (including multinational).  When more than one trial site 
is open in an EU country, Merck, as the Sponsor, will designate, per country, a national 
principal coordinator (Protocol CI), responsible for coordinating the work of the principal 
investigators at the different trial sites in that Member State, according to national 
regulations.  For a single-center trial, the Protocol CI is the principal investigator.  In 
addition, the Sponsor must designate a principal or coordinating investigator to review the 
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trial report that summarizes the trial results and confirm that, to the best of his/her 
knowledge, the report accurately describes the conduct and results of the trial [Clinical Study 
Report (CSR) CI].  The Sponsor may consider one or more factors in the selection of the 
individual to serve as the Protocol CI and or CSR CI (e.g., availability of the CI during the 
anticipated review process, thorough understanding of clinical trial methods, appropriate 
enrollment of subject cohort, timely achievement of trial milestones).  The Protocol CI must 
be a participating trial investigator.
Compliance with Trial Registration and Results Posting Requirements10.4
Under the terms of the Food and Drug Administration Modernization Act (FDAMA) and the 
Food and Drug Administration Amendments Act (FDAAA), the Sponsor of the trial is solely 
responsible for determining whether the trial and its results are subject to the requirements 
for submission to the Clinical Trials Data Bank, http://www.clinicaltrials.gov.  Merck, as 
Sponsor of this trial, will review this protocol and submit the information necessary to fulfill 
these requirements.  Merck entries are not limited to FDAMA/FDAAA mandated trials. 
Information posted will allow subjects to identify potentially appropriate trials for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate trial locations and trial site contact information.    
By signing this protocol, the investigator acknowledges that the statutory obligations under 
FDAMA/FDAAA are that of the Sponsor and agrees not to submit any information about this 
trial or its results to the Clinical Trials Data Bank.
Quality Management System10.5
By signing this protocol, the Sponsor agrees to be responsible for implementing and 
maintaining a quality management system with written development procedures and 
functional area standard operating procedures (SOPs) to ensure that trials are conducted and 
data are generated, documented, and reported in compliance with the protocol, accepted 
standards of Good Clinical Practice, and all applicable federal, state, and local laws, rules and 
regulations relating to the conduct of the clinical trial.
Data Management10.6
The investigator or qualified designee is responsible for recording and verifying the accuracy 
of subject data.  By signing this protocol, the investigator acknowledges that his/her 
electronic signature is the legally binding equivalent of a written signature.  By entering 
his/her electronic signature, the investigator confirms that all recorded data have been 
verified as accurate.
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
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Publications10.7
This trial is intended for publication, even if terminated prematurely. Publication may include 
any or all of the following: posting of a synopsis online, abstract and/or presentation at a 
scientific conference, or publication of a full manuscript.  The Sponsor will work with the 
authors to submit a manuscript describing trial results within 12 months after the last data 
become available, which may take up to several months after the last subject visit in some 
cases such as vaccine trials.  However, manuscript submission timelines may be extended on 
OTC trials.  For trials intended for pediatric-related regulatory filings, the investigator agrees 
to delay publication of the trial results until the Sponsor notifies the investigator that all 
relevant regulatory authority decisions on the trial drug have been made with regard to 
pediatric-related regulatory filings. Merck will post a synopsis of trial results for approved 
products on www.clinicaltrials.gov by 12 months after the last subject's last visit for the 
primary outcome, 12 months after the decision to discontinue development, or product 
marketing (dispensed, administered, delivered or promoted), whichever is later.
These timelines may be extended for products that are not yet marketed, if additional time is 
needed for analysis, to protect intellectual property, or to comply with confidentiality 
agreements with other parties.  Authors of the primary results manuscript will be provided 
the complete results from the Clinical Study Report, subject to the confidentiality agreement. 
When a manuscript is submitted to a biomedical journal, the Sponsor's policy is to also 
include the protocol and statistical analysis plan to facilitate the peer and editorial review of 
the manuscript.  If the manuscript is subsequently accepted for publication, the Sponsor will 
allow the journal, if it so desires, to post on its website the key sections of the protocol that 
are relevant to evaluating the trial, specifically those sections describing the trial objectives 
and hypotheses, the subject inclusion and exclusion criteria, the trial design and procedures, 
the efficacy and safety measures, the statistical analysis plan, and any amendments relating to 
those sections.  The Sponsor reserves the right to redact proprietary information.
For multicenter trials, subsequent to the multicenter publication (or after public disclosure of 
the results online at www.clinicaltrials.gov if a multicenter manuscript is not planned), an 
investigator and his/her colleagues may publish their data independently.  In most cases , 
publication of individual trial site data does not add value to complete multicenter results, 
due to statistical concerns.  In rare cases, publication of single trial site data prior to the main 
paper may be of value.  Limitations of single trial site observations in a multicenter trial 
should always be described in such a manuscript.
Authorship credit should be based on 1) substantial contributions to conception and design, 
or acquisition of data, or analysis and interpretation of data; 2) drafting the a rticle or revising 
it critically for important intellectual content; and 3) final approval of the version to be 
published. Authors must meet conditions 1, 2 and 3.  Significant contributions to trial 
execution may also be taken into account to determine au thorship, provided that 
contributions have also been made to all three of the preceding authorship criteria.  Although 
publication planning may begin before conducting the trial, final decisions on authorship and 
the order of authors’ names will be made based on participation and actual contributions to 
03XKX6
Product:  MK-5172 92
Protocol/Amendment No.: 052-04 
MK-5172-052-04 Final Protocol 04-Jun-2014
the trial and writing, as discussed above. The first author is responsible for defending the 
integrity of the data, method(s) of data analysis and the scientific content of the manuscript.
The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or 
presentations regarding this trial 45 days prior to submission for publication/presentation. 
Any information identified by the Sponsor as confidential must be deleted prior to 
submission; this confidentiality does not include efficacy and safety results. Sponsor review 
can be expedited to meet publication timelines.
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